Galmydar  Protocol  
Version 4.1, 2022- 12-06 Confidential  Page 1 of 49  
Protocol Title:  Development and Translation of Generator -Produced PET Tracer for 
Myocardial Perfusion Imaging.   
Principal Investigator: [INVESTIGATOR_51671] K. Woodard, M.D.  
Professor of Radiology  Washington University School of Medicine Mallinckrodt Institute of Radiology [ADDRESS_826737]. Louis, Missouri, [ZIP_CODE] Tel: [PHONE_12871] 
Fax: [PHONE_12872] E-mail: [EMAIL_11815]
  
IND Sponsor -Investigator: Vijay Sharma, Ph.D. 
Professor of Radiology Washington University School of Medicine  Mallinckrodt Institute of Radiology [ADDRESS_826738]. Louis, Missouri, [ZIP_CODE] 
Tel: [PHONE_12873] 
Fax: [PHONE_12872] E-mail: [EMAIL_11816]
 
Exploratory Investigational New Drug ( Sponsor -Investigator  eIND)  
Investigational Drug:  [68Ga]Galmydar 
FDA IND Number : 157468 
IND Date of Activation:  August 11, 2021 
IRB/HRPO:  202107042 
RDRC:  925  
Protocol Version Date, Number:  December 06 2022, Version 4.1   
  

Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Protocol  
Version 4.1, 2022- 12-06 Confidential  Page 2 of 49 REVISION HISTORY 
Date  
(yr-mo-day) Version  Regulatory 
Committee  Revision History  
2021-06-24 1.0 RDRC  Original submission. Approvable letter received . 
2021-06-29 2.0 n/a RDRC revisions  recommended  to the P rotocol , version 2.[ADDRESS_826739]/Stress C onsent, version 2.0: 
1. The interval between the rest and stress [68Ga]Galmydar PET 
acquisitions should be no less than [ADDRESS_826740]/Stress group: 13N-ammonia data acquisition revised to 10-min list-
mode (if the anterior -posterior diameter  of the chest  is >50cm increase  
to 15-min).  
2021-07-09 2.0 IRB Initial submission.  
2021-12-13 2.1 IRB Revised Protocol from version 2.0 to 2.1  
Bottom of pg. 20 
 
Whole- body PET image acquisition from head to mid- thigh. 
Imaging of subjects will be at three time points spanning from 
immediately after injection up to 4 -hours after [68Ga]Galmydar 
injection. A low -dose spi[INVESTIGATOR_25457] (120 kVp, 50 mAs) will be 
obtained for attenuation correction. Begin whole -body PET image 
acquisition from the head to mid -thigh immediately post 
[68Ga]Galmydar injection for 60- min and repeat at [ADDRESS_826741] the [68Ga]Galmydar.  
2022-07-[ADDRESS_826742]/stress  
Changing galmydar imaging time from “up to 75 mins” to “90 mins”  
Changing rest/stress from 2 days to possibly 3 days 
Changing 2 IVs to possibly 1 IV   
    
    
 
  
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022-12-[ADDRESS_826743]. Louis, Missouri [ZIP_CODE] Tel: [PHONE_12874] E-mail: [EMAIL_11817]
 
Robert J. Gropler, M.D.     
Washington University School of Medicine  [ADDRESS_826744]. Louis, Missouri, [ZIP_CODE] Tel: [PHONE_12875] E-mail: [EMAIL_11818]
 
Richard Laforest, Ph.D. Washington University School of Medicine  [ADDRESS_826745]. Louis, Missouri, [ZIP_CODE] Tel: [PHONE_12876] E-mail: [EMAIL_11819]
 
Michael Nickels, Ph.D.  
Washington University School of Medicine  [ADDRESS_826746]. Louis, Missouri [ZIP_CODE] Tel: [PHONE_12877] E-mail: [EMAIL_11820]
 
Richard Wahl, M.D.  
Washington University School of Medicine  [ADDRESS_826747]. Louis, Missouri, [ZIP_CODE] Tel: [PHONE_12878] E-mail: [EMAIL_11821]
 
  
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-[ADDRESS_826748]/stress Group  ...................................................................................................... [ADDRESS_826749]/Stress Group .................................................................................................... [ADDRESS_826750]/Stress Group .................................................................................................... 15 
4.5 
EARLY DISCONTINUATION OF PARTICIPANTS  ...................................................................15 
4.6P REMATURE WITHDRAWAL AND REPLACEMENT OF PARTICIPANTS  ...............................15 
5 INVESTIGATIONAL STUDY DRUG  ..........................................................................16 
5.1D RUG DESCRIPTION  ...........................................................................................................16 
5.2D RUG HANDLING , PREPARATION , AND RELEASE  .............................................................16 
5.3D RUG ADMINISTRATION  ....................................................................................................16 
5.3.1 Dosage Variance  ..................................................................................................... 16 
6 STUDY PROCEDURES  .................................................................................................17 
6.1S CREENING ASSESSMENTS  .................................................................................................17 
6.2PET/CT  IMAGING  ..............................................................................................................18 
6.2.1 PET Imaging Assessments and Preparation  ........................................................... 18 
6.3D OSIMETRY GROUP - PET/CT  IMAGING  ..........................................................................[ADDRESS_826751]/STRESS GROUP - PET/CT  IMAGING  ........................................................................[ADDRESS_826752]/Stress [68Ga]Galmydar PET MPI  ......................................... [ADDRESS_826753]/Stress 13N-Ammonia  PET MPI  ............................................ 22 
7 SAFETY ASSESSMENTS  ..............................................................................................23 
7.1C LINICAL LABORATORY TESTS  .........................................................................................23 
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-[ADDRESS_826754]/Stress group .................................................................................................... [ADDRESS_826755] STRESS GROUP  ..........................................................................................................25 
8.1.1 PET Images  ............................................................................................................. 25 
8.1.2 MPI [INVESTIGATOR_604200] ................................................................................................... 25 
8.1.3 Coronary Angiography Interpretation..................................................................... 26 8.1.4 Kinetic Modeling for Imaging Quantification to Calculate Myocardial Uptake, MBF, 
and Retention ....................................................................................................................... 26 
9 STATISTICAL PLAN  .....................................................................................................27 
9.1S
AMPLE SIZE JUSTIFICATION  .............................................................................................27 
10 REGULATORY AND SAFETY REPORTING  ...........................................................28 
10.1 REGULATORY COMPLIANCE .......................................................................................28 
10.2 SAFETY EVENT DEFINITIONS  ......................................................................................28 
10.2.1 Investigational Drug................................................................................................ 28 10.2.2 Adverse Event  ......................................................................................................... 28 
10.2.3 Suspected Adverse Reaction  ................................................................................... 28 
10.2.4 Adverse Reaction  .................................................................................................... 29 
10.2.5 Serious Adverse Event ............................................................................................ 29 
10.2.6 Life-threatening....................................................................................................... 29 
10.2.7 Unexpected  ............................................................................................................. 30 
10.3 C
A[LOCATION_003]LITY AND SEVERITY ASSESSMENT ...................................................................30 
10.3.1
 Severity/Intensity  .................................................................................................... 30 
10.3.2 Attribution  ............................................................................................................... 31 
10.4 DOCUMENTING ADVERSE EVENTS  .............................................................................31 
10.5 FOOD AND DRUG ADMINISTRATION MANDATORY REPORTING  ...............................31 
10.5.1 “7-day” Reportable Events  ..................................................................................... 32 
10.5.2 “15-day” Reportable Events ................................................................................... [ADDRESS_826756] MANDATORY REPORTING  .....................................33 
10.6.1 IRB/HRPO Definitions  ........................................................................................... 33 
10.6.2 Reporting Events to IRB/HRPO ............................................................................. 34 
10.7 REPORTING TO RADIOACTIVE RESEARCH DRUG COMMITTEE  ................................35 
10.8 TIMEFRAME FOR REPORTING REQUIRED EVENTS  ....................................................35 
TABLE 1 - REPORTABLE EVENTS  ......................................... ERROR ! BOOKMARK NOT DEFINED . 
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 6 of 49 11 EXPECTED RISKS  .........................................................................................................37 
11.1 [68GA]GALMYDAR RISKS ............................................................................................[ADDRESS_826757] .......................................................................................................... 37 
11.3.2 [68Ga]Galmydar and 13N-Ammonia PET  ................................................................ 38 
11.4 REGADENOSON  ............................................................................................................39 
11.5 PET/CT  IMAGING SCANNER  ......................................................................................39 
11.6 INTRAVENOUS CATHETER PLACEMENT  .....................................................................39 
11.7 QUESTIONNAIRES  ........................................................................................................39 
11.8 BREACH OF CONFIDENTIALITY  ..................................................................................39 
11.9 OTHER RISKS  ...............................................................................................................40 
12 DATA SAFETY MONITORING PLAN .......................................................................40 
13 DATA COLLECTION, RETENTION, AND DATA MANAGEMENT  ....................40 
13.1 DATA COLLECTION FORMS  ........................................................................................40 
13.2 RECORDS MANAGEMENT  ............................................................................................41 
13.3 RETENTION AND AVAILABILITY OF RECORDS  ...........................................................41 
13.3.1 Archival of Imaging Data ....................................................................................... 41 
14 PROTECTIONS, RIGHTS, AND CONFIDENTIALITY ...........................................42 
14.1 INFORMED CONSENT  ...................................................................................................42 
14.2 CONFIDENTIALITY  ......................................................................................................42 
14.2.1 Certificate of Confidentiality  .................................................................................. 43 
14.3 DATA PROTECTION  .....................................................................................................43 
14.4
 DATA SECURITY  ..........................................................................................................43 
14.5 FUTURE USE OF DATA/ DATA SHARING  .....................................................................[ADDRESS_826758]  ..............................................................................................44 
15.4 PARTICIPANT COMPENSATION  ...................................................................................45 
16 ATTACHMENTS  ............................................................................................................45 
TABLE 2. SCHEDULE OF ACTIVITIES –DOSIMETRY GROUP  ...................................................46 
TABLE 3. SCHEDULE OF ACTIVITIES –REST/STRESS GROUP  .................................................47 
17 REFERENCES  .................................................................................................................49 
 
  
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 7 of 49 1 BACKGROUND 
While exploring structure -activity relationships of organic ligands possessing an N4O2 donor core  
[1-3], we identified a gallium-68- radiopharmaceutical (named herein as 68Ga-Galmydar) that 
demonstrates high extraction into the myocardium of mice, rats, and rabbits while also  displaying 
efficient clearance from the blood pool. Additionally, [68Ga]Galmydar is recognized by [CONTACT_621080]1 P -
glycoprotein (Pgp) [ 4] and Breast Cancer Resistance Protein (BCRP, ABCG2) [ 5] as their efficient 
transport substrate, and thus it exploits transporter -mediated excretion pathways from the blood 
and liver, resulting in high heart/blood and heart/liver ratios  60-minute post injection. Live cell-
imaging of rat cardiomyoblasts using Galmydar (fluorescent probe) show s  its localization within 
the mitochondria following permeation within cells indicat ing excellent corr elation with 
radiotracer uptake data [4,5]. [68Ga]Galmydar micro  positron emission tomography 
(PET)/ computed tomography (CT) imaging of rat and rabbit hearts show high myocardial uptake 
and high target/background contrast. Following ligation of the left anterior descending (LAD) 
coronary artery in rat and rabbits, PET/CT imaging clearly showed the hypoperfused region of the 
left ventricle wall. These hypoperfused regions of the myocardium correlated well to the same ex vivo regions by [CONTACT_621081]. [
68Ga]Galmydar has also shown sensitivity 
in monitoring ischemia caused by [CONTACT_621082], also with 
positive correlation of the ischemic region with ex vivo histology. Radiation dosimetry studies in mice extrapolated to human dosimetry estimates using Medical Internal Radiation Dosimetry (MIRD ) methodology and employing FDA guidelines (21 CFR 312) of maximum allowable dose 
to any organ of 50 mSV indicate an allowable maximum injection dose of 8 mCi in humans. This 
is comparable to 
18F-Flurpi[INVESTIGATOR_359532], another  myocardial perfusion imaging ( MPI) agent undergoing 
Phase 3 studies. Importantly, 6[68Ga]Galmydar does not demonstrate any remarkable clinical 
pathology (toxicology) in critical organs following intravenous administration of a single dose 
(1000 fold excess of an IV imaging dose) of an unlabeled agent into rats over 14 days. Finally, 
compared to 13N-ammonia  (a positive control) , [68Ga]Galmydar also  demonstrates similar 
radiotracer characteristics and, in particular, comparable  myocardial first pass extrac tion of about 
70-90% so that regaden osone- induced stress myocardial perfusion and myocardial blood flow 
(MBF) quanti fication  employing kinetic modeling should be comparable [6,7,8 ]  
Thus, this study is designed to demonstrate feasibility of [68Ga]Galmydar for the noninvasive 
detection and characterization of subclinical and clinically -manifest coronary artery disease 
(CAD) in conjunction with PET by [CONTACT_621083]  13N-amm onia PET rest and stress 
studies in human subjects (n=20, 10 males and 10 females). Secondary aims are to evaluate 
dosimetry, biodistribution, and safety, and imaging characteristics following a single injection in normal healthy volunteers at rest (n=8, 4 males; 4 females).  
1.[ADDRESS_826759] certain limitations, such as low sensitivity, poor spatial 
resolution, attenuation artifacts, slow liver clearance, and nonlinearity of MBF at high flow rates. 
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-[ADDRESS_826760] pass 
extraction, low spatial resolution because of the higher positron range, and short radionuclide half -
life due to both potential oversaturation of the detectors at the beginning of the acquisition due to 
injected high dose, and low count statics and suboptimal signal/noise ratios at later time points. Conversely, Gallium -68 based agents offer tremendous advantages as potential PET MPI [INVESTIGATOR_621002].  
Using Gallium- 68, Galmydar incorporates four important components into its pharmacophore 
design: a ) a rationale built upon exploiting transporter -mediated efflux pathways (Pgp and BCRP 
substrates) to facilitate exc retion from neighboring tissues, such as liver and blood, to allow high 
heart -to-liver and heart -to-blood ratios enabling  high target/ background ratios, b) moderately 
hydrophobic cationic probes possessing a delocalized positive charge on their molecular  surface 
to allow penetration of myocardium in response to favorable negative plasma - and mitochondrial 
transmembrane potentials, thereby [CONTACT_621084] -pass extraction and minimal washout from 
myocardium during imaging sessions, c ) a PET agent that incorporates a generator -produced 
radionuclide, 
68Ga (t1/2 = 68 min), to allow production of the radiopharmaceutical independent of 
the availability of a nearby [CONTACT_621085], and d) a potential technology conducive for business models 
of kit distributions comprising a ligand with a long shelf -life, thereby [CONTACT_621086]. These combined elements indicate that further development of 
[68Ga]Galmydar and its translation is based upon the strong scientific premise .  
Also, using both rats and rabbits, micro -PET and nano- single photon emission computed 
tomography ( SPECT ) imaging directly show ed high heart uptake of [67Ga]Galmydar and rapid 
clearance from  the liver within [ADDRESS_826761], the faster kinetics and short half-life of [
68Ga]Galmydar may lead to improved dosimetry over 18F-Flurpi[INVESTIGATOR_359532], another 
mitochondrial complex I targeted MPI [CONTACT_119944]. Moreover, Complex I  deficiency, which is clinically 
and genetically heterogeneous, can present with hypertrophic cardiomyopathy that could either be 
isolated or associated with other comorbidities.  . Therefore, the lower uptake of a given 
mitochondrial C omplex I targeted agent, such as 18F-Flurpi[INVESTIGATOR_621003]. Compared with the performance of 18F-Flurpi[INVESTIGATOR_621004] , the design of [68Ga]Galmydar is based upon an established and successful biochemi cal 
model for development of MPI [CONTACT_238361].  Importantly, the robust biochemical validation of 
Galmydar  in  cellulo   (radiotracer,  and  optical imaging assays) and in mice, rat, and rabbit models 
of both permanent and transient LAD ischemia , with response to pharmacological stress, 
toxicology studies in rats, and  dosimetry  studies  in  vivo,  provide  us  with  a  sound  platform  
for  further versatile molecular imaging probe s for quantifying myocardial perfusion and MBF in 
humans.  
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 9 of 49 1.2 Study Rationale 
1.2.1 Dosimetry Group  
The successful implementation of [68Ga]Galmydar in humans could provide a new mechanism -
driven tracer for PET MPI, and successful realization of aims could ultimately take PET MPI [INVESTIGATOR_621005], where an 18F-distribution 
business model woul d have limitations. [68Ga]Galmydar PET MPI [INVESTIGATOR_621006] (MFR= stress MBF / rest MBF that carries important diagnostic and 
prognostic information) that may play an additional important role to evaluate or monitor the 
effectiveness of preventive medical care or the treatment response on the function of the heart vessels in CAD individuals. These benefits combined with the minimal risks weight the ratio in favor of moving the PET radiotracer [
68Ga]Galmydar into human subjects. This component of the 
study will determine the biodistribution and calculate the radiation dosimetry of [68Ga]Galmydar 
in normal healthy volunteers. Our radiation dosimetry studies in mice [9] extrapolated to human 
dosimetry estimates using MIRD methodology suggest an allowable maximum injection dose of 
8 mCi in humans. The maximum Effective Dose for one 8 mCi intravenous administration of 
[68Ga]Galmydar and three whole -body CT scans with CT attenuation scans results in a gender 
average radiation d ose of 2.84 rem that is well within 57% of the allowable annual dose for 
radiation workers.  
1.2.[ADDRESS_826762]/stress Group  
A rest/stress myocardial 13N-ammonia PET/CT is clinically indicated for the detection of flow -
limiting, obstructive coronary artery disease (CAD). Myocardial perfusion PET provides images 
of a higher quality than SPECT, due to higher spatial and contrast resolution, higher scanner sensitivity , and accurate attenuation correction. In addition, the concurrent quantification of 
myocardial  blood flow (MBF) affords the assessment of hyperemic MBF during pharmacologic 
vasodilation and at rest and, thus, the computation of the  myocardial flow reserve (MFR= MBF  
stress/MBF rest). The concurrent assessment of hyperemic MBF and/or MFR aids in the identification and characterization of multi- vessel CAD, microvascular dysfunction, and 
prognostication.   
We will compare the results of [
68Ga]Galmydar PET/CT MPI [INVESTIGATOR_621007] 13N-ammonia  
PET/CT MPI [INVESTIGATOR_2993] a group of [ADDRESS_826763] MPI [INVESTIGATOR_621008] 
(ICA) as part of their routine standard -of-care (n=10), and half with normal SPECT MPI [INVESTIGATOR_621009] (n=10).  Patients referred for ICA will undergo their  [68Ga]Galmydar and 13N-
ammonia PET/CT MPI [INVESTIGATOR_621010]. In addition, as a completely normal control, 
another 10 subjects without symptomatology or known cardiovascular disease  will also undergo 
both 13N-ammonia PET/CT MPI [INVESTIGATOR_1238] [68Ga]Galmydar PET/CT MPI .  In total 30 patients or normal 
human subjects will be studied. 
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 10 of 49 1.3 Risks and Benefit s  
[68Ga]Galmydar shows critical traits desirable in PET MPI. Additionally, despi[INVESTIGATOR_621011] a concern, 
preclinical toxicity studies were conducted and thoroughly investigated according to FDA 
guidelines for new radiopharmaceuticals. The s mall animal toxicity report is located in the 
appendices of the initial IND submission.  
In summary, a non- GLP 14 -day single dose exploratory toxicity study of Galmydar was performed 
in male and female Sprague Dawley rats ( study number, 2682- 207370NI, Innotiv Maryland 
Heights, Missouri). T he toxicity of Galmydar, a radiopharmaceutical diagnostic drug, was studie d 
when administered as a single intravenous (IV) dose to male  and female Sprague Dawley rats.  Ten 
animals per sex from each group were euthanized for postmortem examination 24 hours after dose 
administration and 5 animals per sex from each group were euthanized for postmortem 
examination  on Day 14 after administration. 
Each treatment group (Group 1 and Group 2) was comprised of 15 male and 15 female Sprague 
Dawley rats.  On Day 1, r ats were administered either the vehicle control (Group 1) or 0.8 mg/kg 
Galmydar (Group 2) via IV injection at a dose volume of 1 mL/kg. 
Physical examinations were conducted prior to randomization into groups. Clinical observations 
were recorded hourly at 1, 2, and [ADDRESS_826764] -dose and once daily on Days 2–14.  Body weights 
were measured prior to initiation of dosing on Day 1 and daily thereafter.  Mortality observations 
were recorded once daily (PM observations).  Blood samples for the evaluation of clinical chemistry and hematology endpoints were collected on Day [ADDRESS_826765] article- related effects on body weight, clinical observations, clinical 
pathology or microscopic findings, a single IV administration of 0.8 mg/kg of Galmydar was well -
tolerated in male and female Sprague Dawley Rats at both 24 hours (Day 2) and 14 days after 
dosing.  
The findings above decrease the likelihood that human toxicity will be a hurdle. While information 
in humans is not yet available, our preliminary animal data shows high agreement in MPI 
[INVESTIGATOR_621012] [
68Ga]Galmydar and 13N-ammonia. The success  of this study of [68Ga]Galmydar  
in human subjects  could provide a mechanism -driven tracer for PET MPI, and ultimately take PET 
MPI [INVESTIGATOR_621013] , wherein 18Fluorine 
distribution business models have limitations , with requirements for nearby [CONTACT_621087] . 
Overall, [68Ga]Galmydar PET MPI [INVESTIGATOR_621014]: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-[ADDRESS_826766]. 
2 STUDY OBJECTIVES  
2.1 Primary Objective  
The primary objective of the proposed study is to evaluate the potential of [68Ga]Galmydar  
PET/CT MPI [INVESTIGATOR_621015]. We will evaluate  
[68Ga]Galmydar PET/CT MPI [INVESTIGATOR_621016] 13N-ammonia PET/CT MPI  [INVESTIGATOR_621017] (MBF) in patients with suspected or known coronary arter y disease 
(CAD) undergoing clinical SPECT MPI . In addition, perfusion and MBF findings with 
[68Ga]Galmydar  will be compared to the results of coronary morphology or stenosis severity in 
those patients undergoing invasive coronary angiography (ICA) based on abnormal SPECT MPI. 
The performance of rest/stress [68Ga]Galmydar PET/CT in comparison to 13N-ammonia PET/CT  
in normal subjects without cardiovascular disease will be performed as a control. 
2.2 Secondary Objectives 
To evaluate dosimetry, biodistribution, and safety, and imaging characteristics following a single  
[68Ga]Galmydar  injection in normal healthy volunteers at rest.  
[ADDRESS_826767] of all clinical investigations with the administration of 
[68Ga]Galmydar . A Form FDA [ADDRESS_826768] (IRB)/Human Research Protection Office (HRPO), the Radioactive Drug Research Committee (RDRC), and receipt of the study activation letter from the 
Food and Drug Administrati on (FDA).  
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 12 of 49 4 STUDY DESIGN AND METHODS  
A single center , phase 0/1 clinical imaging study designed to assess the role of [68Ga]Galmydar 
PET/CT imaging in human subjects.  
4.[ADDRESS_826769]/stress groups. Healthy adult normal 
volunteers (n=8, 4 males; 4 females) for whole- body imaging ( dosimetry group) and patients who 
had a prior clinical SPECT MPI [INVESTIGATOR_621018] .  
Thirty (30) subjects will be  enrolled in  the rest/stress group. Symptomatic patients (n=20) will 
have undergone a SPECT MPI [CONTACT_5148]. Ten patients in this group will have had a study 
positive for ischemia in two myocardial segments and referred for invasive coronary angiography (ICA) as part of their routine standard-of- care. [
68Ga]Galmydar PET imaging will occur prior to 
intervention. The other ten patients will have a normal SPECT MPI [INVESTIGATOR_621019]. S ubjects 
(n=10) who are asymptomatic and without history of cardiovascular disease  will serve as a normal 
controls. 
4.[ADDRESS_826770] meet the inclusion 
criteria . An individual who meets any of the exclusion criteria will be excluded from participation 
in the study.  
4.2.1 Dosimetry Group  
Healthy adult normal volunteers will be enrolled in the dosimetry group.   
[IP_ADDRESS] Inclusion criteria  
• Healthy men and women, 18–99 years of age and any race;  
[IP_ADDRESS] Exclusion criteria  
• Inability to receive and sign informed consent;  
• Positive urine screen for drugs of abuse at screening or before dosing or over -the-counter 
drug use or herbal preparations within  the 2- week  period prior to enrollment;  
• Participation  in another research  study with  a study drug, including a diagnostic or 
therapeutic radiopharmaceut ical, to be administered  during this  study or which  was or 
will be administered  within  10 half -lives  of the radiopharmaceutical.  
• Severe claustrophobia; 
• Pregnant or breastfeeding. 
• Body mass index < 18 kg/m2 or > 40 kg/m2. 
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-[ADDRESS_826771]/Stress  Group  
Twenty  symptomatic patients will have undergone a SPECT MPI [CONTACT_5148]. Ten of these 
patients will have had a study positive for ischemia in two myocardial segments and referred for 
invasive coronary angiography (ICA) as part of their routine standard -of-care. [68Ga]Galmydar 
PET imag ing will occur  prior to intervention. The other ten patients will have had a negative for 
ischemia  SPECT MPI [INVESTIGATOR_621019]. Ten healthy  adult normal volunteers, who are 
asymptomatic , without history of cardiovascular disease or significant cardiovascular risk factors , 
will serve as control subjects. 
Asymptomatic  normal controls and symptomatic patients who have undergone a SPECT MPI 
[INVESTIGATOR_621020], will undergo a rest/stress  
[68Ga]Galmydar PET MPI [INVESTIGATOR_621021]/stress 13N-ammonia PET MPI [CONTACT_4490] a minimum of a  3-day 
separation.  
[IP_ADDRESS] Inclusion  Criteria   
• Male and female, 18- 99 years of age and any race;  
• Have had a prior clinical SPECT MPI [INVESTIGATOR_621022] (ICA)  or have had a prior clinical SPECT 
MPI [INVESTIGATOR_621023]; 
[IP_ADDRESS] Exclusion Criteria  
• Inability to receive and sign informed consent;  
• Percutaneous coronary intervention (PCI) or coronary artery by[CONTACT_15806] (CABG) 
within [ADDRESS_826772] and PET 
examination; 
• Participants who have received chemotherapeutic agents within 6 months of enrollment; 
• Heart failure (left ventricular ejection fraction ≤ 35%);  
• Known non- ischemic cardiomyopathy;  
• Inability to undergo pharmacologic stress testing with regadenoson (Lexiscan). 
Contraindications include:  
o Symptomatic bradycardia or second to  third degree atrioventricular (AV) block;  
o Pre-existing obstructive lung disease  with active wheezing , i.e., COPD, asthma 
with active wheezing that precludes the safe administration of the pharmacological 
stress agent according to the approved label; 
o Uncontrolled and severe hypertension (e.g. systolic blood pressure >200 mmHg, 
diastolic blood pressure >110 mmHg); 
o Baseline hypotension (e.g. systolic blood pressure < 90 mmHg, diastolic blood 
pressure <50 mmHg); 
• Women who are pregnant or  breastfeeding ; 
• Severe claustrophobia; 
• Weight ≥ 500 lbs (weight limit of PET/CT table)  
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 14 of 49 • Administration  of any  diagnostic or therapeutic radiopharmaceutical,  not part  of this  
study, within  a period either  prior to  or after equal  to 10 half -lives  of the 
radiopharmaceutical.  
• Any condition that in the opi[INVESTIGATOR_621024], limit the participant’s ability to tolerate the research procedures or 
interfere with collection of the data such as:  
o Inability to lie still or  unable to tolerate a supi[INVESTIGATOR_621025] a 60-minute PET scan due to chronic back/shoulder pain or arthritis 
as assessed by [CONTACT_26853]/or medical history; 
o Current or past history of major medical illness , i.e., severe kidney or liver 
problems; 
o Patients who suffer an intervening clinical event such as worsening angina pectoris 
or myocardial infarction or whom undergo a myocardial revascularization 
procedure or have myocardial ischemia at rest;  
4.[ADDRESS_826773]/ Stress group 
from the community through the Research Participant Registry/Volunteer for Health (VFH) Program at Washington University in St. Louis ( https://vfh.wustl.edu
). 
Study patients enrolled in  the rest/stress group will be for the assessment of the efficacy of 68Ga-
Galmydar . Patients referred for routine SPECT MPI [INVESTIGATOR_621026]/outpatient clinics at Barnes -Jewish Hospi[INVESTIGATOR_307]/Washington Univers ity in St. 
Louis will be recruited.   
Participants ’ electronic health record s (EHR) will be accessed to review general health information  
for contraindications to planned study procedures  and confirm pre -eligibility . A study team 
member will call potential subjects to discuss the study and answer any questions. Participant s 
who verbally agree to participate will be scheduled for study visits.  
4.[ADDRESS_826774] two, (2) normal volunteers will be separated by 2- [ADDRESS_826775]/stress group. 
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 15 of 49 4.4.1 Dosimetry Group  
Eight healthy adult normal  volunteers (4 males and 4 females) will be enrolled in the dosimetry 
group and undergo whole-body PET/CT imaging with 68Ga-Galmydar.  
4.4.[ADDRESS_826776]/Stress  Group  
For the rest/stress group, we will recruit [ADDRESS_826777] set will be symptomatic patients 
(n=2 0) who have undergone a SPECT MPI [CONTACT_5148]. Half of these patients will have had a 
study positive for ischemia in two myocardial segments and referred for invasive coronary 
angiography (ICA) as part of their routine standard- of-care (n=10). Subjects will undergo 
[68Ga]Galmydar PET/CT prior to any intervention. The second half of these patients will have had 
a normal SPECT MPI [INVESTIGATOR_621019] (n=10). A second set of subjects who are normal, 
asymptomatic, and without a history of cardiovascular disease will serve as controls (n=10) . 
4.[ADDRESS_826778] ration  during the PET/CT MPI [INVESTIGATOR_621027] ’s opi[INVESTIGATOR_621028] 13N-ammonia PET study, the participant may be allowed to continue participation. The 
stress portion of the 13N-ammonia PET study will be removed. The participant will only undergo 
the rest portion of the 13N-ammonia PET study. 
4.[ADDRESS_826779] a study team member, e.g., study coordinator or by [CONTACT_5583] a 
withdrawal letter to the Principal Investigator  [INVESTIGATOR_621029]. 
Attempts will be  made to discuss with the participant the reasons for withdra wal and the 
importance of the study evaluations.  
Include documentation of reason(s) for discontinuation or withdrawal in the enrollment log. Withdrawn p articipants are not allowed to re -enroll into the study. Participants who do not 
complete all protocol- required procedures are replaced to ensure adequate evaluable data.  
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 16 of 49 5 INVESTIGATIONAL STUDY DRUG  
5.1 Drug Description  
The investigational study drug is 68Ga-Galmydar . Gallium- 68 is a positron- emitting radioisotope 
that is  produced from a  68Ge/68Ga generator with a physical half -life of  67.7 minutes. An 
Investigator’s Brochure does not exist for this radioactive drug. The pharmacological properties 
and formulation are described in detail in the Chemistry, Manufacturing, and Control Data section of the IND application.  
5.2 Drug Handling, Preparation, and Release 
Handling of all radioisotopes will be conducted under the auspi[INVESTIGATOR_621030] (WUSM). [
68Ga]Galmydar will be produced under 
the le adership of the Director of the WUSM Cyclotron Facility, and under the supervision of the 
Associate Director of the Cyclotron Production and the Director of the Radiopharmacy. Trained personnel perform the preparation and quality control tests for the rele ase of [
68Ga]Galmydar under 
the supervision of the radiopharmacist  in charge.  
5.3 Drug Administration 
The Sponsor -Investigator will adhere to the procedures and requirements in accordance with 
applicable policies of the Radiation Safety Committee (RSC) at Washington University and the U.S. Nuclear Regulatory Commission (NRC). 
A PET -certified medical professional will draw, administer, and assay the dosage in a dose 
calibrator before and after the administration  of all radiotracers .   
The Dosimetry group will receive one single intravenous administration of 8 mCi ± 20% (6.4‒9.6 
mCi) of 
68Ga-Galmydar. The Rest/Stress Group will receive two intravenous administrations  of 
68Ga-Galmydar , 4 mCi ± 20% (3.2‒4.8 mCi) during rest and 6 mCi ± 20% ( 4.8-7.2 mCi)  during 
the stress of  [68Ga]Galmydar on the PET MPI [INVESTIGATOR_621031] -1. The acceptable mass for each  
[68Ga]Galmydar administration is ≤ 10 µg. On Imaging Day- 2, subjects will receive two single 
intravenous administrations each of 10 mCi ± 20% (8‒12 mCi) of N -[ADDRESS_826780] provide written approval to the imaging facility within 48- hours after a verbal 
approval. All members of the research team will comply with the Washington University Radiation 
Safety Committee Policy on Dispensing of Radiopharmaceutical Dosages for Human Research Subjects.  
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 17 of 49 6 STUDY PROCEDURES  
The Sched ule of Activities (SoA)  tables for the Dosimetry group  and Rest/ Stress group 
summarizes the study assessments and procedures , see Attachments . The results of all assessments 
and evaluations will be recorded on the case report forms. The PI [INVESTIGATOR_11637]- investigator delegated by 
[CONTACT_978] [INVESTIGATOR_621032] . 
The research study tea m will be maintain s tudy logs, e.g., screening and enrollment logs of 
participant s with details of screen  failures , dropouts and adverse event log.   
6.1 Screening Assessments  
The coordinator will review the informed consent form and address questions or concerns with the 
participant and family/friends. Relevant medical history includes current and past 
diseases/illnesses and concurrent medications, as well as surgical and family m edical history. A 
brief physical exam will be conducted by [CONTACT_079] [INVESTIGATOR_1461]. A designee is one 
who is a qualified, engaged member and protocol trained to assess participants. Exams are 
performed  at baseline prior to the [68Ga]Galmydar  injection to determine if the participant is 
suitable to undergo study procedures and for subject readiness prior to discharge from the imaging center.  
Screening will include the following procedures and evaluations  to ensure participants meet 
inclusion and exclusion criteria. 
• Written informed consent will be obtained prior to performing any research procedures; 
• Demographics, including gender, date of birth, race, and ethnicity; 
• Medical history, including family history and surgical history (e.g., pre -existing conditions 
and shoulder or chest trauma) as obtained from participants and available medical records, 
as described below ; 
• PET/CT contraindications; 
• Concomitant medications  review , including non- prescription medicines, vitamins, herbs, 
and supplements; 
• Body weight and height measurements ; 
• A brief physical exam; 
• Vital sign measurements , inclu ding systolic and diastolic blood pressure, heart rate, and  
respi[INVESTIGATOR_697], body temperature; 
• 12-lead ECG ; 
• For women of childbearing potential, a urine pregnancy test must be completed, documented, and confirmed as negative within 24- hrs or on the day of the PET scan . 
Confirm participant is not breastfeeding and agrees not to become pregnant (refrain from sexual activity or is currently using a  medically approved method of contraception) to 
continue for at least 24-hours post- injection  of 
68Ga-Galmydar ;  
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 18 of 49 • Clinical Laboratory Testing: clinical safety labs includes a complete blood count, 
comprehensive metabolic panel, and urinalysis. All participants will have  up to two IV 
catheter s inserted one in each  arm. In dosimetry patients, one IV will be used for the 
collection of blood samples for the lab tests  to include serum metabolites, and the second 
will be used  for the administration of 68Ga-Galmydar . For patients enrolled in the rest/stress  
group, one IV catheter will be used  for the [68Ga]Galmydar administration and the  second 
IV will be used for the administration of the pharmacological stress agent,  regadenoson.  
 
6.2 PET/CT Imaging  
Imaging will be co nducted on the preferred scanner, the Siemens Biograph Vision PET/CT. T he 
Biograph TruePoint/True View may be used alternatively  in the event of a  schedule conflict  or 
scanner problem. The  scanners are located adjacent to each other  in the Center for Clinical Imaging 
Research (CCIR) at the Washington University School of Medicine (WUSM) and Barnes -Jewish 
Hospi [INVESTIGATOR_307] (BJH) in St. Louis.  
The CCIR allows participants to undergo research -related imaging protocols in a safe environment. 
The CCIR is fully equipped for the treatment of medical emergencies, including cardiac arrest 
(crash -cart, intubation equipment, and defibrillator) , and is served by [CONTACT_621088]. 
The CCIR Facility operates in compliance with the Joint Commission on Accreditation of 
Healthcare Organization (JCAHO), and the American College of Radiology (ACR). All facilities operate in compliance with the safety guidelines for imaging and for privacy as directed by [CONTACT_621089] 1996 (HIPAA) and the Nuclear Regulatory 
Commission (NRC).   
PET radiopharmaceuticals will be  produced at Washington  Universi ty School  of Medicine 
(WUMS) -Mallinckrodt Institute  of Radiology (MIR) Cyclotron  Facility.   For investigational PET 
drugs for human use produced under an Investigational New Drug (IND) application in accordance with 21 CFR Part 312. WUMS MIR Cyclotron Facility follows the requirement for 
production of research radiopharmaceuticals in 21 CFR Part 212, Current Good Manufacturing 
Practice (CGMP) For Positron Emission Tomography Drugs, by [CONTACT_621090] <823>, Radiopharmaceuticals for Positron Emission Tomography (PET) —Compounding, Investigational, and Research U ses.  
6.2.[ADDRESS_826781]/ Stress group subjects who undergo the stress PET MPI [INVESTIGATOR_621033]-containing medication or dipyridamole fo r at least [ADDRESS_826782] 24 hours before 
the PET perfusion examination . 
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 19 of 49 The following assessments and procedures will be performed for PET imaging  visits : 
• Confirm eligibility. Review  concomitant medications and any changes in health since the 
screening if assessments were performed on a separate day. Repeat between imaging days;  
• Confirm or perform and document a negative urine pregnancy test for women of 
childbearing potential for each imaging day; 
• Subjects will be requested to use the restroom to empty their bladder prior to radiotracer injection and discharge from the imaging facility;  
• Place one peripheral intravenous (IV) catheter for the administration of radiotracer 
injection and draw blood samples for safety labs. Both the dosimetry group and the 
rest/stress group will have a second contralateral IV catheter placed . In the dosimetry 
group, one IV will be used for collection of safety labs and radiotracer metabolites and one IV will be used for the administration of [
68Ga]Galmydar .  In the rest/stress patients, one 
IV will be used for the administration of [68Ga]Galmydar   and one for the admini stration 
of the pharmacological stress agent, regadenoson; 
• Collect blood and urine samples for clinical safety lab tests for [68Ga]Galmydar participants 
at screening to be used f or a baseline pre -injection measurement  and repeated after the 
imaging prior t o discharge post [68Ga]Galmydar  injection and ; 
• Perform a brief physical exam  for [68Ga]Galmydar participants . The screening exam may 
be used for baseline pre -injection measurement and repeated  post [68Ga]Galmydar 
administration; 
• Place the participant on the imaging table in supi[INVESTIGATOR_621034] d.  To ensure participant comfort, place a pi[INVESTIGATOR_621035]; 
• Place e lectrode s on the participant ’s chest for continuous  ECG monitoring and capturing 
of 12- lead ECG . Place a blood pre ssure cuff on the opposite a rm used for the 
adminis tration of the radiotracer . Continue to monitor  ECG -rhythm and HR until  imaging 
is completed; 
• Obtain vital sign (VS) measurements and 12- lead ECG at the time points listed below and 
repeat as needed  for [68Ga]Galmydar participants . VS include heart rate, respi[INVESTIGATOR_697], 
and diastolic and systolic blood pressure, body temperature . Obtain vital signs (BP and 
HR) and 12- lead ECG  as required per clinical protocol for the rest/stress Ammonia PET 
MPI [CONTACT_3449].  
o Baseline:  VS ( BP, HR, RR, and body temperature ) and a 12-lead ECG within 60-
min prior to injection, repeat if >60- min; 
o Pre-injection: BP, HR, and RR within 15- min; 
o Post- injection: BP, HR, and RR within 5 -min and 15- min, and  hourly during 
imaging visit; 
o End of imaging scan:  BP, HR, and RR; 
o Prior to Discharge:  VS ( BP, HR, RR, and body temperature ) and a 12- lead ECG.  
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 20 of 49 • Instruct pa rticipants  to not move arms, head, or bend knees throughout the study to reduce 
motion artifacts;  
• To reduce respi[INVESTIGATOR_621036], have participant lie 
quietly for 2-3 minutes before acquiring scout image; 
• Participants  will undergo a CT scan for attenuation correction (CT -AC) (50 mAs). Prior to 
acquiring each CT -AC, provide participant specific instructions to  not take deep breaths 
during the CT -AC acquisition. This is to reduce respi[INVESTIGATOR_621037]. During 
the CT -AC scan, the p articipants will be instructed to perform normal end -expi[INVESTIGATOR_621038] -holds;    
• After completion of the PET/CT study, a lignment of the hea rt as seen on the PET and th e 
CT images should  be inspected. In the case of a misalignment, the heart should  be 
re-aligne d manually and image r econstruction r epeated to ensure there are no artifacts of 
attenuation correction created by [CONTACT_621091]-regis tration of the CT and PET dat a. Image s will 
be ins pected by [CONTACT_621092]; 
• Prior to discharge from the CCIR  to home or transfer to the CTRU, c onfirm participants’ 
contact [CONTACT_621093]-up. Provide the participant study team contact 
[CONTACT_3031], (i.e., phone number) should an untoward reaction occur; 
• For all regadenoson stress PET MPI  [CONTACT_315347]: 
o A physician (cardiologist) will be present;  
o Obtain 12- lead ECG , BP and HR pre and post regadenoson injection. 
o Obtain BP and HR every minute for at least [ADDRESS_826783] regadenoson injection and 
monitor ECG rhythm strip. 
o Aminophylline will be readily available to attenuate severe or persistent adverse reactions. Administer slow intravenous injection (50 mg to 100 mg over 30 to 60 
seconds) at least 1 -minute after radiotrac er injection. 
6.3 Dosimetry Group  - PET/CT Imaging  
Healthy adult normal volunteers  enrolled in the dosimetry group will come to the Center for 
Clinical Imaging Research (CCIR) facility, a Washington University facility, located on the 10
th 
floor of Barnes -Jewish Hospi[INVESTIGATOR_621039].  
The following assessments and procedures will be performed: 
• VS, 12- lead ECG, safety labs, and a brief physical exam pre and post injection and prior to 
discharge from the CCIR to home or transfer to the CTRU as described above; 
• All required safety assessments  prior to the administration  of [68Ga]Galmydar and monitor 
ECG rhythm and HR as described above . Monitor ECG -rhythm and HR during imaging; 
• Administer an intravenous bolus injection of  8 mCi ± 20% (6.4‒9.6 mCi) with a mass of 
≤ 10 µg of [68Ga]Galmydar followed by a 10 mL normal saline flush; 
• Whole- body PET image acquisition from head to mid-thigh. Imaging of s ubjects will be at 
three time points spanning from immediately after injection up to 4- hours after 
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 21 of 49 [68Ga]Galmydar injection. A low -dose spi[INVESTIGATOR_25457] (120 kVp, 50 mAs)  will be obtained 
for attenuation correction. Begin whole -body PET image acquisition from the head to mid -
thigh immediately post [68Ga]Galmydar injection for 60- min and repeat at [ADDRESS_826784]/Stress  Group  - PET/CT Imaging  
On Imaging Day-1, all participants  enrolled in t he rest/stress group will come to the CCIR facility 
for < 24-hours for  screening, pre and post rest/stress  [68Ga]Galmydar  PET MPI  [INVESTIGATOR_621040].  
On Imaging D ay-2, all participants will report directly to the CCIR facility for the rest/stress 
13N-Ammonia  PET MPI . [68Ga]Galmydar and 13N-ammonia imaging visits will be separated by a 
minimum of [ADDRESS_826785]/stress group will come to 
the CCIR for screening, pre [68Ga]Galmydar PET MPI  [INVESTIGATOR_621041] r est imaging. 
On Day -[ADDRESS_826786]  [68Ga]Galmydar 
PET MPI [INVESTIGATOR_621040].  On Imaging D ay-3,  participants will report to the CCIR facility for 
the rest/stress 13N-Ammonia PET MPI.  
6.4.[ADDRESS_826787] /Stress [68Ga]Galmydar PET MPI  
[IP_ADDRESS] Rest [68Ga]Galmydar PET 
• Perform all required safety assessments  pre-injection of [68Ga]Galmydar and monitor ECG 
rhythm and HR as described above . Obtain baseline VS and ECG (BP, HR, and RR) within 
15-min [68Ga]Galmydar  pre-injection;   
• Administer an intravenous bolus injection of 4 mCi ± 20% (3.2‒4.8 mCi)  with a mass of 
≤ 10 µg of [68Ga]Galmydar followed by a 10 mL normal saline flush.  
• Begin up to a  30-min list-mode data acquisition for a single bed position at the level of the 
heart  immediately post-injection; 
• Remove subject  from the scanner . Transfer participant to CTRU for a break. 
• The interval between the rest and stress [68Ga]Galmydar PET  acquisitions should be no 
less than 2 hours and no greater than 4 hours.  
[IP_ADDRESS] Stress  [68Ga]Galmydar PET 
• Perform all required safety assessments pre -injection of regadenoson and [68Ga]Galmydar  
as described above. Monitor ECG rhythm and HR continuously during the PET scan; 
• Administer a rapid (10- sec) regadenoson intravenous injection (0.4 mg/5 mL), followed by 
5 mL saline flush; 
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 22 of 49 • 30-sec post regadenoson injection, a dminister a maximum intravenous bolus injection of   
6 mCi ± 20% ( 4.8-7.2 mCi) with a mass of ≤ 10 µg of [68Ga]Galmydar  followed by a [ADDRESS_826788] regadenoson injection 
before injecting the radiotracer;  
• Begin up to a 30- min list-mode data  acquisition for a single bed position at the level of the 
heart  immediately post-injection; 
• Perform all required  safety assessments post- injectio n of 68Ga-Galmydar , end of imaging  
and prior to discharge from the imaging facility as described above;  
• Transfer participant to CTRU for post imaging assessments and procedures prior to 
discharge as described above.  
6.4.[ADDRESS_826789]/Stress  13N-Ammonia  PET MPI  
[68Ga]Galmydar and 13N-ammonia imaging visits will be separated by a minimum of 3- days but 
not before the participant follow- up phone call is complete  for capturing adverse events following 
the administration of 68Ga-Galmydar . Participants will report to the CCIR .  T he PI, study 
cardiologist or trained designee will evaluate symptomatic patients to confirm there has  been no 
change in clinical status since the [68Ga]Galmydar PET MPI . If in the judgment of the 
investigator/designee the patient’s clinical condition has changed since the  [68Ga]Galmydar 
imaging day, the patient may undergo the rest only 13N-ammonia PET imaging scan or be 
rescheduled for Imaging D ay-2, 13N-ammonia PET MPI . 
[IP_ADDRESS] Rest  13N-Ammonia  PET  
• Review of concomitant medications and any changes in health between the rest/stress PET 
MPI [INVESTIGATOR_621042]-1, 68Ga-Galmydar, and imaging day-2, 13N-ammonia; 
• Confirm a negative urine pregnancy test for women of childbearing potential; 
• Obtain baseline v ital signs (BP and H R) pre and post 13N-ammonia injection  as described 
above. Continue to monitor ECG -rhythm and HR until imaging is completed; 
• Administer an intravenous bolus injection of 10 mCi ± 20% (8‒12 mCi) of 13N-ammonia 
followed by a 10 mL normal saline flush. 
• Begin a 10-m in list-mode data acquisition (if the anterior-posterior diameter  of the chest  is 
>50cm  increase to 15-min) for a single bed position at the level of the heart  immediately 
post- injection; 
• Obtain vital signs (BP and HR) and 12- lead ECG  as required per clinical protocol ; 
• Remove patient from scanner for a break. The interval between the rest and stress 
13N-ammonia acquisitions should be per the clinical protocol ( no less than 1-hour ).  
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 23 of 49 [IP_ADDRESS] Stress 13N-Ammonia  PET  
• Obtain baseline vital sign measurements and 12- lead ECG pre -injection of regadenoson or 
13N-ammonia  administrations . Continue to monitor  ECG -rhythm, and HR, until stress PET 
MPI [CONTACT_88014];  
• Administer regadenoson intravenous injection (0.4 mg/5 mL) over 10 sec, followed by 
5-10 mL saline flush; 
• Obtain vital signs (BP and HR) and 12- lead ECG  as required per clinical protocol ; 
• [ADDRESS_826790] regadenoson injection, a dminister an intravenous bolus injection of 10 mCi ± 
20% (8‒12 mCi) of 13N-ammonia followed by a [ADDRESS_826791] regadenoson injection before injecting the radiotracer;  
• Begin a 10- min list-mode data acquisition (if the anterior-posterior diameter  of the chest  is 
>50cm  increase to 15-min) for a single bed position at the level of the heart  immediately 
post- injection; 
• Obtain vital signs (BP and HR) as described above prior to discharge.  
7 SAFETY ASSESSMENTS  
Safety will be evaluated by [CONTACT_621094], physical findings, electrocardiograms, clinical laboratory tests values, and the incidence of adverse events (AE). AEs will be reviewed for potential significance and clinical importance.  
7.[ADDRESS_826792] (CLIA) certified lab that will perform all laboratory blood tests for this study. A list of the current established reference ranges are available on the General Information  page of 
the Barnes -Jewish Hospi[INVESTIGATOR_307] (BJH) Lab website,
 https://bjhlab.testcatalog.org/ .  
All participants will have  baseline  blood and urine samples obtained for screening and for 
compari son with post- imaging complete blood count, comprehensive metabolic panel, and 
urinalysis. For abnormal changes from baseline , the Investigator or designee will determine if  
additional assessments for clinical significance or change in participant management if needed . 
Any adverse event s/serious adverse events  must also be documented in the case report forms 
(source documents) and appropriately reported . 
Participants may request to receive a copy of their lab results or their rest/stress  13N-Ammonia 
PET MPI [INVESTIGATOR_621043] -Jewish Hospi[INVESTIGATOR_307] . 
7.2 Vital Sign Measurements  
Vital sign (VS) measurements will be obtained at screening to determine eligibility, at baseline 
within  60-min, within  15-min pre- injection an d within [ADDRESS_826793]- injection of 
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-[ADDRESS_826794] imaging clinical protocol for the N -
ammonia imaging . VS measurements  include heart rate (HR), systolic and diastolic blood pressure 
(BP), respi[INVESTIGATOR_697] (RR), and body t emperature . Temperature will be taken at baseline and prior 
to discharge on imaging days and  as needed. Time points listed may only include BP and HR ; see 
Imaging PET Assessments  section  for details. BP and HR must be obtained at least once prior to 
injection and once post- injection before discharge with the participant in the supi[INVESTIGATOR_2547]. Care 
will be taken to obtain subsequent recordings with the participant in the same position (supi[INVESTIGATOR_621044]).    
 The following variables are considered clinically significant if changes occur from baseline. A 
systolic BP o f < 90 or > 160 mmHg or a diastolic BP of < 50 or > 100 mmHg or a 20 mmHg change  
from baseline  in the SBP or DBP. A heart rate of < 50 BPM or > 100 or a 20 BPM change from 
baseline. A respi[INVESTIGATOR_135890] < 12 or > 20 breaths/min and oral temperature of >100
oF.  
 Participant s who  develop bradycardia (heart rate < 40 BPM, Mobitz 2:1 AV Block (Type 1 or 
Type 2) or QTc  ≥ 500ms ) will be monitored until heart rate and conduction returns to baseline. Any 
abnormalities that meet the definition of an adverse event/ serious adverse event must  be 
documented and appropriately reported. 
7.[ADDRESS_826795] 12- lead electrocardiogram (ECG) will be obtained at screening  for all participants. 
Baseline is within 60- min pre -injection, within [ADDRESS_826796]/Stress  group, ECGs will be obtained per standard-of- care 
rest/stress regadenoson imaging clinical protocol . A study cardiologist delegated by [CONTACT_978] [INVESTIGATOR_621045],  sign, and date.   
 
The following variables are considered abnormal if changes occur from baseline. A PR interval of 
<120 or >200 msec, QRS interval <50 or >100 msec, RR interval  <600 or >1000 msec, or QT 
interval ≥ [ADDRESS_826797] degree A V block and/or 
QTc  ≥[ADDRESS_826798]- injection, will be monitored until the ECG returns to normal and will be excluded 
from additional study procedures. Any abnormalities that meet the definition of an adverse event / 
serious adve rse event must be documented and appropriately reported. 
7.[ADDRESS_826799]/stress participants  by [CONTACT_621095] [
68Ga]Galmydar to confirm the subject’s well- being and to ascertain  if an adverse event (AE)  
occurred  post- imaging procedures.  If any of the specified days are not business days, the phone 
call may occur the following business day. In the event of a serious AE or unanticipated problem, 
we will ask participants  to return to the i maging facility for evaluation/safety visit. Follow -up may 
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-[ADDRESS_826800] of an in-person visit(s) or additional telephone contact. Study staff may access medical 
records during the study to follow AE/problems that developed because of study participation. We 
will follow all participant AEs until resolution or stabilization, as evaluated by [CONTACT_978] [INVESTIGATOR_1461]. 
Study participation is complete at the end of the follow -up or the ﬁ nal monitoring visit of serious 
AEs. 
7.4.[ADDRESS_826801] [68Ga]Galmydar injection .  
7.4.[ADDRESS_826802]/Stress group  
Rest/stress participants will receive a phone call within 2-[ADDRESS_826803] [68Ga]Galmydar injection. 
The follow -up phone call to collect safety data must be complete  before scheduling a participant 
for the rest/stress 13N-ammonia PET imaging visit.  
[ADDRESS_826804] Stress Group  
8.1.1 PET Images 
All images will be reconstructed at 5 -min (a delay to allow for blood-pool  clearance) using 
reconstruction matrix at 168 × 168 × 109, with a pi[INVESTIGATOR_206021] (2 × 2 × 2 mm). Scatter, decay, and 
random corrections will also be applied to the reconstructed images. Static myocardium perfusion 
and gated myocardial function images will be generated by [CONTACT_281115][INVESTIGATOR_621046] [ADDRESS_826805] mode data acquisition. Dynamic image sequence will be reconstructed for quantitative blood flow evaluation. Comparative quantitative blood flow will be evaluated with Carimas and also using 
QPET or  4DM software
65 available through our departmental image processing servers 
(MIM/Vista and Hermes). Myocardial image processing techniques will then be applied to the gated datasets. The myocardial wall segment analysis will be performed using the 17- segment 
American Heart Association model
66.  
8.1.[ADDRESS_826806] certified radiologists (Drs. Schindler, 
Woodard, and Gropler) in nuclear medicine. Both overall qualitative diagnosis and semi -
quantita tive 17 segment with 5 point (0=normal, 4=absent tracer uptake) scoring will be employed 
in the independent blind read out by [ADDRESS_826807]/stress perfusion and gated images as normal, ischemic, ischemic and scar, or scar. A 
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 26 of 49 patient will be defined as MPI [INVESTIGATOR_621047]. Summed stress scores (SSS), 
summed rest scores (SRS), and summed difference scores (SDS) will also be calculated 64. 
Absolute regional myocardial blood flow will also be reported. 
8.1.3 Coronary Angiography Interpretation 
All coronary angiograms will be interpreted using quantitative coronary analysis (QCA) .  Separate 
research analysis of the anonymized data will be performed. A coronary stenosis will be considered 
present when there is = 50% diameter stenosis in any epi[INVESTIGATOR_131270]. The presence of 
one or more coronary stenosis will be used to define the presence of significant CAD. Presence or 
absence of wall motion abnormality will not be considered in interpreting the presence or absence 
of CAD. The determination of the presence or absence of CAD will be  strictly related to coronary 
stenosis in the native coronary arteries; arteries with patent stents will be classified as no significant CAD, regardless of evidence of prior myocardial infarction. Arteries with by[CONTACT_621096].  
8.1.4 Kinetic Modeling for Imaging Quantification to Calculate Myocardial Uptake, MBF, 
and Retention 
Carimas software incorporates the needed compartmental models suitable for this study. 
[
68Ga]Galmydar MBF (at rest and stres s) will be quantitatively analyzed using a [ADDRESS_826808] 1-
compartment model is governed by [CONTACT_621097]: K1 represents activity from blood to myocardium, and is related to blood flow and K 2 characterizes the activity from myocardium to 
the blood. In general, blood flow is related to K1 by a flow -dependent extraction fraction with a 
relationship of the form: K1 = EF (Extraction Fraction).MBF with EF = (1- exp(-(
αMBF + β)/MBF) 
with α and β being tracer dependent parameters. Importantly, [13N]-NH 3 is a validated quantitative 
blood flow tracer which will be modeled using the 2- compartment model described earlier. 
Further, [13N]-NH [ADDRESS_826809] pass extraction of  90% and will serve as a reliable reference control. 
In both of these models, the effects of partial recovery of the counts in the myocardium and spi[INVESTIGATOR_4382] -
over from the blood pool have been fitted along the model parameters.  
To investigate the relationship b etween the radiotracer extraction and flow, the tracer -derived MBF 
data will be plotted against both the absolute microsphere -derived MBF values and 13N-ammonia 
MBF values. This relationship will allow us to characterize the flow dependent extraction fract ion 
for the radiotracer. We will first determine K1 from compartmental modeling and then  determine 
the extraction fraction parameters ( α and β) by [CONTACT_36730] [68Ga]Galmydar K1 to radioactive 
microsphere MBF and [13N]-NH 3 derived MBF. We will then compare and analyze this extraction 
fraction to flow dependent extraction of other known MBF tracers, such as 99mTc-sestamibi, 
99mTc-Tetrafosmin, 201Tl or 82Rb. Furthermore, [68Ga]Galmydar excretes from blood pool much 
faster than 99mTc-sestamibi due to low logP value, and heart/blood (5min/60 min) ratios in mice 
are also superior to that of 18F-Flurpi[INVESTIGATOR_359532] ( [68Ga]Galmydar: %ID/g; 12.0/0.1= 120 REF; 
18F-BMS -747158: 9.5/0.5 = 1914; 120/19 = 6.3 folds), these data point to superior flow dependent 
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 27 of 49 extraction fraction of [68Ga]Galmydar than 99mTc-sestamibi. Furthermore, the MFR (myocardial 
flow reserve), which is defined as the ratio of maximal to basal MBF, will be compared between 
the myocardial retention (MFR retention ) and SUV -deriv ed data (MFRSUV) versus both either 
[68Ga]Galmydar MFR (MFR Galmydar ) or 13N-Ammonia MFR (MFR Ammonia ). Because myocardial 
perfusion will be homogeneous, only mean values in the left ventricle will be used in the analysis. These proposed experiments will all ow us to accurately measure this factor in an animal model 
closer to an anatomical reference for application in humans thus providing modeling paradigms to 
enable quantification of the myocardial blood flow in humans. MBF will also be evaluated with 
clinic ally approved software such as QPET or 4DM software
65 available through our departmental 
image processing servers (MIM/Vista and Hermes).  
9 STATISTICAL PLAN  
Continuous variables will be expressed as mean (or median) and range or standard deviations. Categorical variables will be expressed as frequencies. The diagnostic efficacy of [
68Ga]Galmydar 
and 13N-ammonia PET MPI [INVESTIGATOR_621048]. Analysis of diagnostic efficacy will be performed by [CONTACT_73700]. The analysis of diagnostic certainty will be a modified majority rule in which the median rating will be used when three readers have 3 different ratings. Similarly, summaries and 
comparisons of Summed Stress Score (SSS), the Summed Rest Score (SRS), and the Summed 
Difference Score (SDS) measures will use the median of the results of 3 blinded readers. The 
sensitivity and specificity and corresponding 95% confidence interval of each radiotracer will be report ed. Normalcy rate will be determined in the patients with a low likelihood of CAD and no 
ICA and be calculated as % of patients with normal/probably normal studies. Agreement for the 
diagnostic efficacy (presence/absence of CAD) between [
68Ga]Galmydar and 13N-ammonia PET 
MPI [INVESTIGATOR_621049] a kappa statistic. The agreement between the quality of scan will be 
assessed using a weighted kappa and the SUV uptake will be assessed using an intra -class 
correlation coefficient. The ROC  analysis  will be perfo rmed  using 17 segment  model (according 
to the American  Heart  Association  Guidelines) to assess the diagnostic efficacy  in detection  of 
obstructive coronary  disease.  The area under ROC and confidence intervals will use the empi[INVESTIGATOR_621050], et al.68 The inter -reader agreement between 3 blinded readers will 
be estimated by [CONTACT_621098] (normal/abnormal) and presented using kappa 
and percent agreement. Intra- reader agreement in each of the reader will be performed by  
[CONTACT_4296] 10% of the repeat images in the blinded read and will be estimated using kappa and 
percent agreement. All tests will be two -sided and a significance level of 5 %.  
9.1 Sample size justification  
While information in humans is not available, our preliminary animal data shows high agreement 
between  [68Ga]Galmydar and 13N-ammonia. Therefore, we expect to see strong agreement 
between the diagnostic efficacies of these two radiotracers in this sample of patients. A sample 
size of 20 patients results in a two -sided 95% confidence interval with a width of 0.26 (lower 
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 28 of 49 limit=0.669, upper limit=0.931) assuming strong agreement between the radiotracers (a kappa of 
0.8) and a standard deviation of 0.3. Sample size calculations were conducted in PASS v14. 
[ADDRESS_826810] (IRB)  /Human Research Protection Office 
(HRPO) and the Radioactive Drug Research Committee (RDRC)/Radiation Safety Office at 
Washington University and the U.S. Food and Drug Administration (FDA). The Sponsor -
Investigator will ensure members of the rese arch team w ill comply with the adverse event 
reporting as described below. 
The Principal Investigator, Sponsor -Investigator, Authorized User, and members of the research 
team will promptly review all available safety information relevant to the safety of the drug, 
including any ﬁndings from another  source not related to this study that suggest a significant risk 
for human subjects . Subjects will be instructed to inform a member of the research team as soon 
as possible  should they experience symptoms of  an adverse even t to begin an adverse event 
evaluation. AE follow -up will occur as ordered by [CONTACT_079] [INVESTIGATOR_1461] . 
Additional follow-up will occur until the abnormal measurements return to baseline or acceptable limits , or until monitoring is no longer warranted  or stabilization as evaluated by a physician. A 
study team member will review the subject’s medical record for clinical history and, if applicable, 
monitor for test results as made available.    
10.[ADDRESS_826811] definitions for reporting will be used: 
10.2.1 Investigational Drug 
The investigational drug named [
68Ga]Galmydar is a radioactive drug held under an Investigational 
New Drug (IND) application.  10.2.2 Adverse Event  
Adverse Event (AE) is any untoward medical occurrence in human subjects who receive the 
investigational radioactive drug 
68Ga-Galmydar, whether or not considered related to the drug. An 
AE (also referred to as an adverse experience)  may include any unfavorable and unintended sign 
(i.e., abnormal lab test finding), symptom, or disease temporally associated with the use of the 
drug, and does not imply any judgement about causality.  
10.2.3 Suspected Adverse Reaction  
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 29 of 49 A suspected adverse reaction is any adverse event that is determined that  there is a reasonable 
possibility that the investigational drug caused the adverse event. For IND safety reporting, 
'reasonable possibility' means there is evidence to suggest a causal relationship between the drug 
and the adverse e vent. A suspected adverse reaction implies a lesser degree of certainty about 
causality than an adverse reaction.  
 
  
10.2.4 Adverse Reaction  
Adverse Reaction means any adverse event caused by [CONTACT_280607]. Adverse reactions 
are a subset of all suspected adverse reactions where there is a reason to conclude that the drug 
caused the event.  
10.2.5 Serious Adverse Event  
An adverse event or suspected adverse reaction is considered serious if the event or reaction, in 
the view of the Principal Investigator, results in any of the following serious outcomes: 
• Death,   
• A life -threatening adverse event as defined as placing the participant at immediate risk of 
death from the AE as it occurred,   
• Initial or prolonged inpatient hospi[INVESTIGATOR_059] (hospi[INVESTIGATOR_621051]  ≥ 24 hours or 
prolongation of a hospi[INVESTIGATOR_621052]),  
• Persistent or significant incapacity or substantial disruption of the ability to conduct normal 
life functions, or 
• Congenital anomaly or birth defect.  
10.2.6 Life-threatening  
An adverse event or suspected adverse reaction is “life- threatening” if, in the view of the Principal 
Investigator , its occurrence places the participant at immediate risk of death. It does not include an 
adverse event or suspected adverse reaction that, h ad it occurred in a more severe form, might have 
caused death.  
Important Medical Events  (IMEs)  are not immediately life -threatening , nor do they place a 
participant at immediate risk of death or require hospi[INVESTIGATOR_059] . Examples of IMEs include allergic 
bronchospasm requiring intensive treatment in the emergency room or at home, or convulsions 
that do not result in inpatient hospi[INVESTIGATOR_059].  IMEs may be serious if in the judgement of the 
Principal Investigator  [INVESTIGATOR_621053].  
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 30 of 49 10.2.7 Unexpected  
An adverse event or suspected adverse reaction is unexpected if is not listed at the specificity or 
severity that is currently  
 observed, or the event is not consistent with the risk information described in the protocol, informed consent form, general investigational plan or elsewhere in the current IND application. 
An Investigator's Brochure does not exist nor is it required for this IND.  The Principal  Investigator 
[INVESTIGATOR_621054].  
Expected adverse reactions are adverse events that are known to occur for the investigational drug 
and should be collected in a standard, systematic format using a severity grading scale. 
Expectedness is assessed based on the awareness of AEs previously observed, not on the basis of what might be anticipated from the properties of the study drug. For risk related to this IND 
protocol, see Expected Risks
 section below.  
10.[ADDRESS_826812] a causal relationship with the investigational drug is a 
reportable adverse event. Any changes, i.e., deterioration or worsening in these condition(s) shall 
be documented and evaluated by [CONTACT_079] [INVESTIGATOR_1461]. AEs with signs and symptoms that are believed to be due to the pre -existing condition(s) will not be reported as an AE 
unless there is an increase in frequency and severity.   
10.3.1 Severity/Intensity  
An adverse ev ent will be classified as one of the following to describe the severity (intensity) and 
any necessary action taken in an attempt to resolve the event:  
• Mild : A mild AE is usually transient in nature and generally not interfering with normal 
activities. Participants are asymptomatic or have mild symptoms; intervention is not indicated.  
• Moderate: A moderate AE is sufficiently discomforting to interfere with normal daily 
activities. Participants may need minimal, local, or noninvasive intervention;  
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 31 of 49 • Severe: Also referred to as medically significant but not immediately life -threatening; 
hospi[INVESTIGATOR_39676]; disabling; limiting self -care 
activities of daily living (ADL). Note that a severe event is not necessarily a ser ious event. 
10.3.2 Attribution  
The degree of certainty about causality will be graded using the following relationship categories:  
• Unrelated : An adverse event is clearly not related to the drug or procedure.  
• Unlikely Related : An adverse event is doubtfully related to the drug procedure.  
• Possibly Related : An adverse event is may be related to the drug or procedure.  
• Probably Related : An adverse event is likely related to the drug or procedure.  
• Definitely Related : An adverse event is clearly related to the drug or procedure.  
For the purposes of regulatory reporting, a causality assessment of unlikely related will be 
managed as “unrelated .” An adverse event that is definitely, probably, or possibly related will be 
managed as “related” and considered a “reasonable possibility” that the drug caused the adverse event and, therefore, meets the criteria for reporting to the FDA . 
10.[ADDRESS_826813] results/findings, regardless of 
suspected causal relationship will be documented in the subjects’ research record. Complete 
appropriate reporting forms according to the guidelines set forth by [CONTACT_130562] 
(IRB) at Washington University Human Research Protection Office (HRPO) and the U.S. Food 
and Drug Administration (FDA).  
Adverse events that are cl assified as reportable will be followed until resolution or stabilization as 
evaluated by a physician. Any new relevant clinically significant findings/abnormalities or 
changes from the subjects’ baseline that meet the definition of an adverse event must a lso be 
recorded and documented as an adverse event. All clinically significant changes, relevant medical 
history and concomitant medications and action taken will be documented in the subjects’ case 
report forms (source document forms). Events that which do not meet the requirements of SAE 
reporting will be reviewed and confirmed by [CONTACT_621099], Data Safety and Monitoring report and the FDA annual report.  
The investigator’s clinical determination of a ny adverse event will be recorded and maintained in 
the subjects’ research record. All AEs shall be documented on the adverse event log maintained in 
the regulatory binder. 
10.5 Food and Drug Administration Mandatory Reporting 
The Principal Investigator [INVESTIGATOR_621055], foreign or 
domestic, including information derived from clinical investigations, animal investigations, 
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-[ADDRESS_826814] notify the Food and Drug Administration (FDA) of any a dverse 
events that are observed or voluntarily reported according to the reporting criteria and timeframe  
as descri bed below.  
10.5.1  “7-day” Reportable Events  
Report any study event that is serious (fatal or life -threatening), unexpected, and associated with 
the use of the investigational drug. Report as soon as possible but no later than 7- calendar days  
following the Sponsor -Investigator/ Principal Investigator’s initial receipt of the information.  
Identify the submission as “7-day IND Safety Report.” 
10.5.2 “15-day” Reportable Events  
Report any study event that is serious, but not fatal or life -threatening, unexpected, and associated 
with the use of the investigational drug. Other findings that suggest significant risk to human 
subjects, any clinically important increased rate of events or any previous unreported adverse event 
that was not initially reportable because the event did not fit the criteria for reporting . Report within 
15-calendar days  from when Sponsor -Investigator/ Principal Investigator ’s initial receipt of the 
information  or determination of the previous event is currently  reportable.  Identify the submission 
as “IND Safety Report.”  
10.5.3 Follow- up Reporting  
The Sponsor-Investigator/ Principal Investigator  [INVESTIGATOR_621056]. Any relevant follow -up information that 
pertains to  an IND safety report previously submit ted will be submitted  within 15-calendar days  
from day zero, date of the 7- day report. Identify the submission as “F ollow-up IND Safety Report.”  
10.5.[ADDRESS_826815] serious AEs, will be 
submitted each year within 60 days of the anniversary of the date that the IND became active, the 
date clinical studies were permitted to begin.  
10.5.5 Reporting Events to the FDA  
IND safety reports may be submitted electronically on an FDA Form 3500A (MedWatch) or in a 
narrative format via secure e- mail, facsimile transmission or telephone  to the FDA  Regulatory 
Project Manager  in accordance with 21 CFR 312.32 to the address below.  
Division Director  
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 33 of 49 U.S. FDA CDER - Div ision of Medical Imaging Products 
Attention: FDA Central Document Room 
5901- B Ammendale Road  
Beltsville, MD [ZIP_CODE] FAX: [ADDRESS_826816] (IRB) at 
Washington University (WU)  and the Human Research Protection Office (HRPO) in accordance 
with WU IRB policies and procedures. The Investigator or designee will report immediately  to the 
IRB any observed or volunteered self -reported adverse event that meets the unanticipated problem 
criteria or if the Investigator believes,  the information meets the exception criteria as described 
below. 
10.6.1 IRB/HRPO Definitions  
[IP_ADDRESS] Unanticipated Problem (UP) involving risks to participants or others:  
• Are unexpected in terms of nature, severity, and/or frequency given the research 
procedures that are described in the protocol and consent form and the characteristics of 
the subject population being studied; and  
• Are related or possibly related to participation in the research; and  
• Suggest that the research places  participants or others at a greater risk of harm including 
physical, psychological, economic, or social harm, than previously known or recognized. 
[IP_ADDRESS] Unexpected adverse drug event:  
Any adverse drug experience , associated with the use of the drug, of which the frequency, 
specificity, or severity is not consistent with the current investigator brochure; or, if an inve stigator 
brochure is not required or available, the specificity or severity of which is not consistent with the 
risk information provided to the participants and the IRB. 
[IP_ADDRESS] Protocol Exceptions and Deviations  
• Protocol exceptions  apply only to a single participant or a singular situation. The IRB is 
required to review and approve a planned protocol change before initiation or 
implementation of a change , except when necessary to eliminate immediate hazards to a 
participant. In the event a situation occurs which requires deviation from the protocol, the Principal  Investigator [INVESTIGATOR_621057] a participant 
has completed  the study. The PI [INVESTIGATOR_621058] a 
reportable event within 10 working days. 
• Protocol deviations  from the investigational plan or protocol that affect the life or physical 
well-being of a participant in any emergency, the Principal Investigator [INVESTIGATOR_621059]. Deviations because of unforeseen 
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-[ADDRESS_826817], 
but will not be reported as a protocol deviation.  
[IP_ADDRESS] Non-Compliance and Serious Non-Compliance  
• Noncompliance  may occur due to lack of knowledge or due to deliberate choice to ignore 
regulations, institutional policies, or  determinations of the IRB. Noncompliance is the 
failure to follow any applicable regulation or institutional policies that govern human 
subjects research or failure to follow the determinations of the IRB.  
• Serious noncompliance  is noncompliance that materially increases risks that results in 
substantial harm to subjects or others, or that materially compromises the rights or welfare 
of participants.  
10.6.2 Reporting Events to IRB/HRPO  
Table 1
 is a s ummary of reportable events that do not  meet the unanticipated problem  definition  
will be reported with the IRB annual continuing review, i.e., IND external safety reports. Federal 
regulations do not require immediate reporting to the IRB of IND/outside safety reports for events that do not meet the criteria outlined in 21 CFR 312.32(c). Thus, IND Safety reports that do not 
meet the regulatory requirement for immediate reporting  will be reported in an aggregate summary 
format at the time of IR B continuing review. 
[IP_ADDRESS] “1-day” Reportable Events  
The Principal Investigator [INVESTIGATOR_621060] a member of the research 
team.   
• Any unanticipated problem involving risk to participants or others and results in the death 
of a participant at WU.  
• An u nexpected adverse drug event that results in the death of a participant at WU.  
• A major deviation that results in the death of a participant at WU.  
[IP_ADDRESS] “10-day” Reportable Events  
The Principal Investigator [INVESTIGATOR_621061] 
10 working days  of the occurrence or notification of the event  to the PI [INVESTIGATOR_1660] a member of the research 
team.  
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 35 of 49 • An unanticipated problem involving risk to participants or others, or a major deviation that  
does NOT result in the death of a participant  at WU . 
• A series of minor d eviations that represent a systemic issue with the conduct of the study. 
• New i nformation that may influence the willingness of subjects to parti cipate in the 
research study, e.g., an interim analysis or safety monitoring report that indicates the 
frequency or magnitude of harms or benefits, or a paper published from another study that 
shows a difference in risks or potential benefits. 
• Participant c omplaints that result from an unanticipated problem or noncompliance. 
• Breach of confidentiality  
• Incarceration of a participant enrolled in the protocol  
• Withdrawal of the p articipant poses a safety issue  
10.7 Reporting to Radioactive Research Drug Committee 
According to applicable policies of the Radioactive Research Drug Committee (RDRC) at Washington University (WU), the Sponsor-Investigator/ Principal Investigator  [INVESTIGATOR_621062] 24 hours to the Chairman of the RDRC. 
10.8 Timeframe for Reporting Required Events  
Table 1  below summarizes the timeframe requirements for reportable events aft er initial receipt of 
the information by [CONTACT_1034]- Investigator (Vijay Sharma, Ph.D.), Principal Investigator (Pamela 
K. Woodard, M.D.), Authorized User (Thomas Schindler, M.D.), and Sub- Investigators, or a 
member of the research team as described above.   
 
    
 
     
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 36 of 49  
  
Table 1 - Reportable Events  
IRB and RDRC REPORTING  FDA REPORTING  
• Any unanticipated problem 
involving risk to participants or 
others and results in the death of a participant.  
• An unexpected adverse drug event that results in the death of 
a participant.  
• A major deviation that results in 
the death of a participant.  The PI [INVESTIGATOR_621063] “ 1-working 
day”. • Any serious (fatal or 
life-threatening), 
unexpected suspected adverse reactions.  
 The IND Sponsor -
Investigator  will report 
to the FDA as soon as possible but no later than “7-calendar days ” 
following initial receipt of the information.  
• An unanticipated problem 
involving risk to participants or others, or a major deviation that does not result in the death of a participant.  
• New information that may influence the willingness of participants to take part in the study, e.g., an interim anal ysis 
or safety monitoring report that 
shows the frequency or 
magnitude of harms or benefits, or a published paper from another study that shows a difference in risks or potential benefits, revised Investigator’s 
Brochure (IB), FDA labeling 
change, a market ing drug 
withdrawal, or DSMB reported safety issue.  
• A series of minor deviations that represent a systemic issue 
with the conduct of the study.  
• Participant complaints that 
result from an unanticipated problem or noncompliance.  
• Breach of confidentiality.  
• Participant withdrawal poses a 
safety issue.  
• Incarceration of an enrolled 
participant.  The PI [INVESTIGATOR_621064] “ 10-working 
days ”. • Any serious, 
unexpected, suspected adverse reactions.  
• Findings from other clinical, animal, or in -
vitro studies that suggest significant human risks.  
• Any clinically 
important increased 
rate of serious suspected adverse reaction.  The IND Sponsor -
Investigator  will report 
to the FDA and all investigators within “15-calendar days ” 
after determining the information qualifies for reporting.  
• Adverse events that do not meet 
the definition of unanticipated 
problem.    
 The PI [INVESTIGATOR_621065].  • Adverse events that 
do not meet the 
definition of serious, 
unexpected, and suspected adverse 
reaction.    The IND Sponsor -
Investigator  will include 
a summary of adverse events in the FDA annual report.  
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 37 of 49 • External IND Safety reports 
(non- WU)  for a cross -
referenced IND drug that does 
not meet the  above  reporting 
requirements.   The PI [CONTACT_133557] a 
summary of external 
IND Safety reports in 
the IRB annual 
continuing review.  • Adverse events that 
do not meet the definition of serious, 
unexpected, and 
suspected adverse 
reaction.    The IND Sponsor -
Investigator  will include 
a summary of exte rnal 
IND Safety reports in the FDA annual report.  
 
11 EXPECTED RISKS  
11.1 [68Ga]Galmydar Risks  
We consider the risk associated with an investigational new PET radioactive drug extremely low 
based on the short half -life of [68Ga]Galmydar  of 68 minutes , the prescribed dosage is at the 
required microdose level, and observations made from  the preclinical toxicity studies that no 
histopathologic changes were attributable to drug toxicity nor were there abnormalities attributable 
to the single drug dose. Despi[INVESTIGATOR_6831], there is nevertheless the possibility of a rare allergic reaction.  
See IND application appendices for the toxicity report. 
Based on common responses to other tracers, we anticipate that some  participants may experience 
dysgeusia (bad taste in mouth), flushing, headache, dizziness or lightheadedness, mild 
gastroenteritis, pruritus, urticaria.  
11.2 13N-Ammonia Risks  
13N-Ammonia  is an FDA approved drug. There are no known side/adverse effects associated with 
the use of 13N-Ammonia other than radiation exposure. 
11.3 Radiation Exposure 
Participants will be  exposed to radiation from  68Ga-Galmydar, 13N-ammonia, and low-dose 
computerized tomography (CT) imaging  conducted on the Vision Edge PET/CT or Biograph-40 
TruePoint PET/CT scanner . The effective dose (ED) calculations are for worst -case scenarios 
depending on the number of CT -attenuation correction ( CT-AC) scans with topogram . An 
additional CT -AC scan with topogram will be performed for participants who may need to be 
rescheduled due to technical problems, e.g., scanner issues, radiotracer failure, or for participants 
who require a break during a  scan and resume imaging after the break.  The risk associated with 
the amount of radiation exposure participants receive during this research study is low and comparable to other everyday risk.  
11.3.[ADDRESS_826818]  
The effective dose (ED) for one whole- body CT protocol conducted at a single time point is 0.49 
rem (50 mAs). A one -bed position low dose CT (50 mAs) over the heart for attenuation correction  
(CT-AC) is 0.18 rem.  
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 38 of 49 11.3.2 [68Ga]Galmydar and 13N-Ammonia PET  
The effective dose for [68Ga]Galmydar is 0.103 rem/mCi (gender averaged). T he effective dose 
for 13N-ammonia is 0.007 rem/mCi.  
 
[IP_ADDRESS] Dosimetry Group  
A single dosage of 8 mCi ± 20% (6.4‒9.6 mCi) with a mass of ≤ 10 µg  is planned for 
[68Ga]Galmydar administration for the Dosimetry group. The  effective dose for a whole-body 
PET/CT imaging protocol includes a single intravenous administration of 8 mCi of 
[68Ga]Galmydar, three whole -body CT scans and four CT-AC scans is 2.81 rem and 2.87 rem for 
male and females.  
[IP_ADDRESS] Rest /Stress  Group  
Participants  will receive two [68Ga]Galmydar intravenous administrations, [ADDRESS_826819] and 
6 mCi during stress for the PET MPI  [INVESTIGATOR_621066] -1. The effective dose for a single 
intravenous administration of 6 mCi of [68Ga]Galmydar is 0.62 rem and 0.41 rem for a 4 mCi 
administration  performed . The acceptable mass of [68Ga]Galmydar is ≤ [ADDRESS_826820] and stress  PET MPI . 
 
• Rest /Stress  [68Ga]Galmydar PET MPI 
[INVESTIGATOR_621067] a rest and stress PET MPI [INVESTIGATOR_621068] [ADDRESS_826821]-AC scans with topogram is 1.40  rem . 
• Rest/Stress 13N-Ammonia PET MPI  
[INVESTIGATOR_621069] a single intravenous administration of [ADDRESS_826822]/stress 13N-Ammonia PET MPI [INVESTIGATOR_621070] [ADDRESS_826823]-AC scans is 0.51 rem.  
• Total Rest/Stress PET MPI   
[INVESTIGATOR_621071] -1, rest/stress [68Ga]Galmydar PET MPI [INVESTIGATOR_621072]-2, rest/stress 13N-Ammonia PET MPI [INVESTIGATOR_621073] 1.[ADDRESS_826824]-
AC scans.  
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 39 of 49 11.4 Regadenoson  
Regadenoson, the pharmacological stress agent may cause a flushed feeling during the  intravenous 
injection. After injection of regadenoson, mild headache, nausea, or dizziness, an irregular and/or 
fast heartbeat, shortness of breath, mild chest pressure or chest pain may ensue for a short while. 
If needed  as prescribed by [CONTACT_39635] (cardiologi st), intravenous aminophylline may be given 
to resolve these side effects.  
11.5 PET/ CT Imaging Scanner  
Other risks may include feeling uncomfortable while lying down during the scan. Participants may experience claustrophobia (anxiety due to being restrained in a confined area) while some 
experience dizziness or feel faint.  If the participant experiences these symptoms and does not wish 
to continue, the study will be stopped immediately. 
There is a rare risk of malfunction of worn or implanted electronic medical  devices during the low -
dose CT attenuation scan conducted prior to the PET scan. Participant screening of such devices 
will be performed by [CONTACT_621100]. The CT scan may 
cause a malfunction of worn or implanted e lectronic medical devices, i.e., pacemaker or a drug 
pump. 
11.6 Intravenous Catheter Placement  
Participants may experience pain, bruising, and/or bleeding at the site of needle ins ertion for the 
intravenous (IV ) catheter.   There is a rare risk of infection from the needle insertion. 
11.7 Questionnaires  
Participants may experience emotional discomfort when answering some questions in the 
questionnaires (i.e., PET /CT safety screening assessments). If any particular question makes the 
participant uncomfortable, the participant may discuss its importance and the need to answer it with a trained interviewer. Participants have the right to refuse to answer any question for any 
reason. If safety screening cannot be completed, the imaging exams will be canceled.  
11.[ADDRESS_826825] been established for sharing the image s and 
reports. The Principal Investigat[INVESTIGATOR_1660] [INVESTIGATOR_1660] a designee communicates any potentially clinically 
meaningful abnormal findings to the participant  and, if the participant permits, to their primary 
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-[ADDRESS_826826]  scan 
and the report will be uploaded to the participant’s electronic health record (EHR). Once the CT  
is part of the EHR, then participants may request additional copi[INVESTIGATOR_621074] a standard m edical record request.  
11.9 Other risks  
There may also be unknown risks. Although allergic or other immediate adverse reactions are not 
anticipated, participants will be monitored in an area where emergency equipment is available. 
There are no alternative metho ds to gather comparable data. 
12 DATA SAFETY MONITORING  PLAN 
In compliance with the Washington University School of Medicine Institutional Data Safety 
Monitoring (DSM) Plan, the PI  [INVESTIGATOR_9042] a DSM report to the IRB /HRPO annually. All 
members of the research team will review safety data as it becomes available. The DSM report 
will include, but not be limited to the protocol title, IRB protocol number, IND number, the 
activation date of the study, the number of subjects enrolled to date, a summary of all adverse events, number of subjects who dropped out/withdrew for any reason whether thought to drug related with a corresponding reason for dropout, and any new information related to the investigational drug or that may aff ect the safety or ethics of the study.  
Drs. Woodard (PI) and Wahl  and the Sponsor-Investigator, and at least one additional sub-
investigator, will review and assess drug biodistribution and safety  data through the 2-[ADDRESS_826827] two (2) normal volunteers prior to imaging of the 
remaining normal volunteers. Upon completion of the review, the study will continue with imaging of the remaining dosimetry subjects  with simultaneous entry of the rest/stress group. 
Asymptomat ic normal controls and symptomatic patients who have undergone a SPECT MPI 
[INVESTIGATOR_621020], will undergo a rest/stress  
[
68Ga]Galmydar PET MPI [INVESTIGATOR_621021]/stress 13N-ammonia PET MPI [CONTACT_4490] a minimum of a 3- day 
separation.  
[ADDRESS_826828] a research chart with case report forms (source document forms) 
designed for documenting all observations and other pertinent study related activity. The research coordinator or designee will document eligibility criteria and other pertinent information such as 
demographic information, imaging visit sessions with pregnancy test results, if applicable and 
administration of radiopharmaceutical, adverse events and any in -person or correspondence with 
participants.  
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 41 of 49 13.2 Records Managemen t 
The Sponsor-Investigator/ Principal Investigator  [INVESTIGATOR_621075]. The Investigator will delegate such tasks to research team members 
to ensure all study files are accurate and organized at all times. The study coordinator will review 
participant research records, including hard copy and electronic, for completion and accur acy. The 
study team will follow best practice guidance with implementation of electronic storage of research 
study documents. Electronic records may be created, maintained , and stored where possible. A 
certified copy of the signed informed consent form may  be stored in a secure web -based data 
storage application that is HIPAA compliant. All electronic records a re password protected in an 
electronic data capture system that is on a (the?)  Washington University Secure Network and in 
compliance with university policies.  Paper records that are required for the study will be stored 
under a 2 -tiered locked system.  
Imaging Safety questionnaires and other imaging data required for radiation safety will be collected in accordance wit h the Code of Federal Regulations (21 CFR 312) procedures and 
requirements governing the use of investigational new drugs and the monitoring of serious adverse events per for th e protocol to allow for oversight of annual radiation exposure of participants.  We 
may share the data with other investigators if a participant takes part in future studies requiring imaging procedures. 
 
13.3 Retention and Availability of Records 
The Sponsor-Investigator/ Principal Investigator  [INVESTIGATOR_621076], and applicable local institutional policies and procedures. IND 
records and reports will be retained for a minimum of 2 years after study discontinuation, or the 
FDA has been formally notified (21 CFR 312.57). Participants  provide consent to authorization 
for the use of private health information. Therefore, all research records, including signed consent 
forms and data/case report forms (source document s) will be retained for at least seven, (7) years 
beyond the close of the study.  
The Sponsor-Investigator/ Principal Investigator  [INVESTIGATOR_621077], the Human R esearch Protection Office or 
Regulatory Agencies, i.e., Food and Drug Administration or National Institutes of Health, the 
source of grant funding. 
13.3.1 Archival of Imaging Data  
Only code numbers will appear on any data and documents to be used for evaluation or statistical 
analysis. Publications emanating from this research will not identify individual patients.  HIPAA 
compliance will be enforced as per Washington University policy and HRPO approval.  
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 42 of 49 Processed and raw PET/CT data will be transferred to the Central Neuroimaging Data Archive 
(CNDA). Request for access to CNDA must be reviewed and approved by [CONTACT_079] [INVESTIGATOR_621078]- investigator.  Data access is limited to approved user roles as well 
as assigned access privileges. CNDA complies with Section 164.[ADDRESS_826829] (HIPAA) that specifies physical safeguards that are required 
for protection of Electronic Protected Health Information (EPHI) to avoid unauthorized disclosure, modification, or destruction. The CNDA system has the functionality to create audit tables used to 
monitor traffic thr ough the system and to identify unauthorized attempts to upload or change 
information or otherwise cause damage. 
14 PROTECTIONS, RIGHTS, AND CONFIDENTIALITY 
14.1 Informed Consent  
The informed consent process will occur in accordance with the Declaration of Helsinki, ICH 
GCP, U.S.  Code of Federal Regulations for Protection of Human Subjects (21 CFR 50.25[a,b], 
CFR 50.27, and CFR Part 56, Subpart A), the Health Insurance Portability and Accountability Act (HIPAA), and applicable institutional research policies and procedures. 
Written informed consent will be obtained from each research participant prior to the initiation of 
any research procedure. All participants will be given ample opportunity to review the informed 
consent form to consider participation in the study, under circumstances that would eliminate 
undue influence, and time to discuss with family and the research team. Participants will be informed of the right to refuse to participate that will not involve a penalty or loss of benefits. A participant may withdraw from study participation at any time without interfering with routine 
clinical care.  The informed consent process will take place in a private area. The Investigator or 
designee will review the consent form with the participant, confirm eligibility criteria and assess the participants’ level of understanding. The informed consent process shall be documented, and a copy of the consent will be provided to the participant. 
14.[ADDRESS_826830] (HIPAA) and by [CONTACT_621101]. Protected Health Information (PHI) on study participants will be managed 
according to Washington University Policies and Security Requirements. Studies are done for 
research purposes only. Reports from patients’ records concerning research observations will not be available to outside medical facilities without written consent of the participant. Participants will be given the contact [CONTACT_621102]’s Privacy Officer for questions or concerns 
about privacy and the use of PHI. 
Electronic data obtained as part of the research project will be stored on a secure network with password access.  Hardcopy data will be stored in a 2 -tiered locked system. The research team will 
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-[ADDRESS_826831]’s 
infor mation. When possible, the research team will de -identify information that could be linked to 
the subject.  
Participant study related electronic data may be saved to Box, a HIPAA compliant cloud- based 
file storage and collaboration tool that allows for file  sharing. Any electronic data saved to local 
computers are encrypted, password- protected with limited access. Participant hardcopy data (e.g., 
participant signed consent forms) will be stored under a 2- tiered locked system with limited access 
to only resea rch team members.  
14.2.[ADDRESS_826832] the privacy of study participants, a Certificate of Confidentiality (CoC) will be issued by [CONTACT_7681] (NIH). This certificate protects identifiable research inform ation from forced disclosure of research participants. It allows the investigator and study 
team members or others who have access to research records to refuse to disclose identifying information on research participants in any civil, criminal, administra tive, legislative, or other 
proceedings, regardless of the type of whether at the federal, state, or local level.  
14.3 Data Protection 
Participants will be a ssigned a unique research ID  code for the research study. Imaging scans and 
the data and study documents produced as a result of the research and used for evaluation or 
statistical analysis are labeled with the ID code and the date of the scan.  
Publications emanating from this research will not identify individu al participants. Reports from 
patients’ records concerning research observations will not be available to outside medical facilities without the written consent of the participant.  
14.[ADDRESS_826833] copy consent forms 
will be stored in a 2 -tiered locked system with limited access to research team members.  
14.5 Future Use of Data/ Data Sharing  
Important elements for data sharing are included in the consent form and are discussed during the informed consent process. All data is coded and linked with the subject’s unique identifier . 
Information generated by [CONTACT_15365], including data and stored blood samples, if applicable  will be  
to be used now and in the future to address research questions in similar fields or other unrelated 
areas. Research investigators may be at Washington University or outside the university at other 
research centers, institutions, or industry sponsor of the research.  
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-[ADDRESS_826834] sharing with the research community. If the participant’s research data is placed in one of these repositories, only qualified researchers who have received prior approval from individuals that monitor the use of the data will be able to look at this information.  
[ADDRESS_826835], the Human Research Protection Office (HRPO) and in accordance with state and federal government regulations standards of Good Clinical Practice, and 
applicable institutional research policies and procedures.  
The Sponsor-Investigator/ Principal Investigator  [INVESTIGATOR_621079]. The protocol and informed consent form will be reviewed and approved by [CONTACT_1744]/ HRPO 
and the Radioactive  Research Drug Committee (RDRC) at Washington University. All subsequent 
amendments will be submitted to IRB/ HRPO and if applicable, the RDRC for approval and other 
applicable committees as needed.  
Washington University complies with the regulations outlined in [ADDRESS_826836] under 21 
CFR 312.57b and 312.64. 
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 45 of 49 15.4 Participant Compensation   
Research participants are compensated for t heir time, research ‐related inconveniences and 
discomforts experienced during the study. Any expenses incurred in reimbursing participants are 
for reasonable and customary medical costs incurred related to the treatment of an adverse event 
experienced that  is determined, in consultation with the Sponsor-Investigator/ Principal 
Investigator , was reasonably related to the administration of the investigational radiotracer, 
68Ga-Galmydar.  
16 ATTACHMENTS   
The S chedule of A ctivitie s (SoA) table s for each group begins on the next page, see Table [ADDRESS_826837]/Stress group . 
   
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 46 of 49 Table 2 . Schedule of Activities –Dosimetry Group  
   Whole -Body PET Imaging   
Procedure  Pre-
Screen(a) Screening 
Visit(b,c) [68Ga]Galmydar      
PET/CT(i) Delayed     
Imaging(i) Discharge(i) Phone  
Follow -
up(j) 
Written Informed Consent(b)  X     
Inclusion/Exclusion Criteria(b) X X     
Adverse Events Monitoring(b)  X X X X X 
Medical Records (EHR)(c)  X X X X X X 
Demographics(b) X X     
Medical History(b) X X     
Concomitant Medication(b) X X    X 
Physical Exam/Evaluation(b)  X   X  
Body Weight and Height(b)  X     
IV line placement(d)   X     
Clinical safety labs(e)  X X  X  
Vital Signs(f,h,i)  X X X X  
12-lead Electrocardiogram(h,j)  X X  X  
Safety Monitoring(j)   X X   
Whole -Body PET/CT imaging(i,k)   X X   
a) A phone call  will be conducted to determine participant interest , eligibility,  and schedule study visits .  
b) Screening will occur in the CCIR facility .  
c) Safety m onitoring for adverse events (AE)  will occur from the time of injection  to the end of 
participation. Participants’ medical records (EHR) are followed in the event of an adverse 
event.                                                                                                                                                                                                                                               
A physician or designee must evaluate participants at baseline  or [68Ga]Galmydar pre-injection  and 
post-imaging before discharge.  
d) Two peripheral IV catheter s will be placed for the [68Ga]Galmydar  injection  and collection of blood 
samples.  
e) Blood and urine samples will be obtained for clinical safety labs (complete blood count, 
comprehensive metabolic panel, and urinalysis) at screening  and post imaging prior to discharge. For 
women of child -bearing potential, a urine pregnancy test must be obtained and confirmed as 
negative. See Safety Assessments  section.  
f) Vital signs will be obtained at screening, baseline within [ADDRESS_826838] imaging session , beginning of each delayed imaging session, 
and prior to discharge from  the imaging facility.  Repeat as needed .  
g) A [ADDRESS_826839] imaging session, and prior to discharge from imaging facility. 
Repeat as needed .  
h) Monitoring during the PET study:  Place a blood pre ssure cuff on the opposit e arm used for the 
radiotracer admin istration to measure b lood pressure  and hea rt rate. Place electrodes on the 
participant ’s chest for continuous  ECG monitoring and electrodes to obtain 12- lead ECG.  
i) Obtain a  low-dose CT -AC (50 mAs) prior to the 8 mCi ±20% (6.4 ‒9.6 mCi) IV injection  of 
[68Ga]Galmydar followed by a [ADDRESS_826840] [68Ga]Galmydar injection  for 30- min and repeat at 2 hours 
and 4 hours.  
j) Phone follow-up will occur within 2- [ADDRESS_826841] 
[68Ga]Galmydar injection. If any of the days are not business days, the follow -up phone call may  
occur the following business day.    
  
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 47 of 49 Table 3. Schedule of Activities –Rest /Stress  Group  
Procedure  Pre- 
Screen(a) Screen ing 
Visit(b) IMAGING DAY -1 
[68Ga]Galmydar      
PET/CT(k) IMAGING DAY -2 
13N-Ammonia  
     PET/CT(l) Phone  
 Follow -
up(o) Rest  Stress  Discharge(m) Rest  Stress  Discharge(m) 
Written Informed Consent   X        
Inclusion/Exclusion Criteria  X X        
Adverse Events(b)  X X X X X X X X 
Medical Records (EHR)(c)  X X X X X X X X X 
Demographics  X X   X     
Medical History(a,d) X X        
Concomitant Medication(b) X X X X  X X  X 
Physical Exam/Evaluation(d)  X      X  
Body Weight and Height(b)  X   X     
IV placement(e)    X   X    
Clinical safety labs(f)  X X X    X  
Vital Signs(g)  X X X X X X X  
12-lead Electrocardiogram(h,i)  X X  X X  X  
Safety Monitoring(g,h,i)   X X X X X X  
PET/CT imaging(j,k,l,m)    X X  X X   
a) A phone call will be conducted to determine participant interest, eligibility, and schedule study visits.  
b) Participants will be admitted to the Clinical and Translational Research Unit (CTRU) facility for 
screening, during the break between rest and stress [68Ga]Galmydar  PET, and post-imaging safety  
assessments before discharge.   
c) Safety monitoring for adverse events (AE) will occur from the time of injection to the end of 
participation. Participants’ medical records are followed in the case of an adverse event.                                                                                                                               
                                                                                                                                              
d) A physician or designee must evaluate participants at baseline or [68Ga]Galmydar pre-injection and 
post-imaging before discharge.  
e) Two peripheral IV lines will be placed for the radiotracer injections, collection of blood samples and 
for the regadenoson administration during the stress PET imaging.   
f) Confirm fasting (≥ 6 hrs). Collect blood and urine samples for [68Ga]Galmydar  safety labs (complete 
blood count, comprehensive metabolic panel, and urinalysis) at screening , baseline, and post imaging 
prior to discharge from the imaging facility. For all women of childbearing potential, a urine 
pregnancy test must be obtained and co nfirmed as negative. See Safety Assessments  section. 
g) Obtain vital signs at screening , baseline rest [68Ga]Galmydar scan within [ADDRESS_826842]-of- care clinical protocol for 
regadenoson stress imaging  scans for both radiotracers, [68Ga]Galmydar and  13N-ammonia . 
h) A 12 -lead ECG will be performed at screening/baseline, within [ADDRESS_826843]-of- care 
clinical protocol.   
i) Monitoring : Place a blood pre ssure cuff on the opposit e arm used for the r adiotracer  admin istration 
to measure b lood pressure  and hea rt rate. Place electrodes on the participant ’s chest for continuous  
ECG monitoring and e lectrod es to obtain  12-lead E CG.  
j) PET/CT imaging: Obtain a low -dose CT- AC ( 50 mAs) prior to each rest and stress radiotracer 
injection. If the same IV line is used for both the regadenoson and radiotracer injections, wait 10-[ADDRESS_826844] regadenoson injection before injecting the radiotracer. 
 
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 48 of 49  
 
k) [68Ga]Galmydar  Imaging Day-1:  
• Rest PET : Administer 4 mCi  ±20% ( 3.2‒4.8 mCi) of [68Ga]Galmydar IV injection followed by 
a [ADDRESS_826845] and stress 
[68Ga]Galmydar PET acquisitions should be no less than 2 hours and no greater than 4 hours.  
• Stress PET MPI : [INVESTIGATOR_107952] a rapid (10 -sec) regadenoson IV injection (0.4 mg/5 mL), followed 
by 5 mL saline flush; 30-sec post regadenoson injection, a dminister 8 mCi  ±20% (6.4‒ 9.6 mCi ) 
of [68Ga]Galmydar IV injection followed by a [ADDRESS_826846]-
mode data acquisition for a single bed position at the level of the heart.   
l) 13N-Ammonia  Imaging Day-2:  
• Rest PET : Administer an IV bolus injection of 10 mCi  ±20% (8‒12 mCi) of 13N-Ammonia  
followed by a [ADDRESS_826847]-mode data acquisition (if 
the anterior -posterior diameter  of the chest  is >50cm  increase to 15-min)  for a single bed position 
at the level of the heart.  The interval between the rest and stress 13N-ammonia acquisitions should 
be no less than 1-hour . 
• Stress PET MPI : [INVESTIGATOR_107952] a rapid (10 -sec) regadenoson IV injection (0.4 mg/5 mL), followed 
by 5 mL saline flush; 30-sec post regadenoson injection, a dminister 10 mCi ±20% (8 ‒12 mCi ) 
of 13N-Ammonia  IV bolus injection followed by a [ADDRESS_826848]-mode 
data acquisition (if  the anterior -posterior diameter  of the chest  is >50cm increase to 15-min)  for 
a single bed position at the level of the heart.   
m) Transfer [68Ga]Galmydar participants to CTRU for post imaging safety assessments and discharge.  
Discharge 13N-Ammonia participants from the CCIR.  
n) Contact [68Ga]Galmydar participants  by [CONTACT_1382] 2-[ADDRESS_826849] [68Ga]Galmydar injection. 
[68Ga]Galmydar and 13N-ammonia imaging visits will be separated by a minimum of 3-days and not 
before the follow- up phone call is complete for capturing participant adverse events following the 
administration of [68Ga]Galmydar . If any  of the days are not business days, the phone call may occur 
the following business day. 
  
Drug: [68Ga]Galmydar Serial Number 0000  
Sponsor -Investigator: Vijay Sharma , Ph.D.   Exploratory Investigational  New  Drug Application  
Galmydar  Proto col 
Version 4.1, 2022- 12-06  Page 49 of 49 17 REFE RENCES  
1) Sharma, V. et al.  Novel gallium (III) complexes transported by [CONTACT_621080]1  P-glycoprotein: 
potential PET imaging agents for probing P -glycoprotein- mediated transport activity in 
vivo. Chem & Biol  7, 335-343 (2000). 
2) Sharma, V. Radiopharmaceuticals for assessment of multidrug resistance P -glycoprotein-
mediated transport activity. Bioconjug .Chem. 15, 1464-1474 (2004). 
3) Sharma, V., Prior, J., Belinsky, M., Kruh, G. & Pi[INVESTIGATOR_99206] -Worms, D. Characterization of 
67Ga/68Ga-radiopharmaceutical for SPECT and PET of MDR1  P-glycoprotein transport 
activity in vivo : validation in multidrug -resistan t tumors and at the blood- brain barrier. J. 
Nucl. Med. 46, 354-364 (2005). 
4) Sharma, V. et al.  A Generator -Produced Gallium -68 Radiopharmaceutical for PET 
Imaging of Myocardial Perfusion. PloS one  9, e109361, doi:10.1371/journal.pone.0109361 
(2014). 
5) Sivapack iam, J., Harpstrite, S. E., Prior, J. L., Mattingly, S. & Sharma, V. 
(67/68)Galmydar: A metalloprobe for monitoring breast cancer resistance protein (BCRP) -
mediated functional transport activity. Nucl. Med. Biol. 43, 191-197, 
doi:10.1016/j.nucmedbio.2015.12.001 (2016). 
6) Sivapackiam J, Sharma M, Schindler TH, Sharma V. PET Radiopharmaceuticals for Imaging Chemotherapy- Induced Cardiotoxicity. Curr Cardiol Rep, 19;22(8):62. doi: 
10.1007/s11886-020-[ZIP_CODE]- z. (2020). 
7) Sivapackiam J., L aforest R., Sharma V.  
68Ga-Galmydar : Preliminary Assessment of its 
Imaging Potential for Monitoring Acute Myocardial Infarction in Rabbits, J Nuc Medicine, (2017), 58 (Supplement 1): 797. 
8) Sivapack iam J., Laforest R., Sharma V. 
68Ga-Galmydar: PET Imaging of  Myocardial 
Infarction in Rabbits and Comparative Blood Flow Analysis in Rats, J Nuc Medicine, (2020), 61 (Supplement 1): 3126. 
9) Sivapackiam, J., Laforest, R. & Sharma, V. 
68Ga-Galmydar: Biodistribution and Radiation 
Dosimetry Studies in Rodents Nucl Med Bi ol, 59, 29–35 (2018).  
 
 